Alterations of Neurotransmitter Receptors in Schizophrenia: Evidence from Postmortem Studies

Referencias bibliográficas

• Abi-Dargham A, Laruelle M, Lipska B, Jaskiw GE, Wong DT, Robertson DW, Weinberger DR, Kleinman JE. 1993. Serotonin 5-HT3 receptors in schizophrenia: A postmortem study of the amygdala. Brain Res 616(1-2): 53–57.
• Abi-Dargham A, Laruelle M. 2005. Mechanisms of action of second generation antipsychotic drugs in schizophrenia: Insights from brain imaging studies. Eur Psychiatry 20: 15–27.
• Aghajanian GK, Marek GJ. 2000. Serotonin model of schizophrenia: Emerging role of glutamate mechanisms. Brain Res Brain Res Rev 31: 302–312.
• Ahlquist RP. 1948. A study of the adrenotopic receptors. Am J Physiol 153: 586–600.
• Akasu T, Ishimatsu M, Yamada K. 1996. Tachykinins cause inward current through NK1 receptors in bullfrog sensory neurons. Brain Res 713: 160–167.
• Akbarian S, Huntsman MM, Kim JJ, Tafazzoli A, Potkin SG, Bunney WE Jr, Jones EG. 1995. GABAA receptor subunit gene expression in human prefrontal cortex: Comparison of schizophrenics and controls. Cereb Cortex 5(6): 550–560.
• Akbarian S, Sucher NJ, Bradley D, Tafazzoli A, Trinh D, et al. 1996. Selective alterations in gene expression for NMDA receptor subunits in prefrontal cortex of schizophrenics. J Neurosci 16: 19–30.
• Albuquerque EX, Pereira EF, Bonfante-Cabarcas R, Marchioro M, Matsubayashi H, et al. 1996. Nicotinic acetylcholine receptors on hippocampal neurons: Cell compartment-specific expression and modulatory control of channel activity. Prog Brain Res 109: 111–124.
• Alonso G, Phan V, Guillemain I, Saunier M, Legrand A, et al. 2000. Immunocytochemical localization of the sigma(1) receptor in the adult rat central nervous system. Neuroscience 97: 155–170.
• Aoki C, Go CG, Venkatesan C, Kurose H. 1994. Perikaryal and synaptic localization of alpha 2A-adrenergic receptor-like immunoreactivity. Brain Res 650: 181–204.
• Apicella P. 2002. Tonically active neurons in the primate striatum and their role in the processing of information about motivationally relevant events. Eur J Neurosci 16: 2017–2026.
• Ariano MA, Fisher RS, Smyk-Randall E, Sibley DR, Levine MS. 1993. D2 dopamine receptor distribution in the rodent CNS using anti-peptide antisera. Brain Res 609: 71–80.
• Ariano MA, Sibley DR. 1994. Dopamine receptor distribution in the rat CNS: Elucidation using anti-peptide antisera directed against D1A and D3 subtypes. Brain Res 649: 95–110.
• Ariano MA, Stromski CJ, Smyk-Randall EM, Sibley DR. 1992. D2 dopamine receptor localization on striatonigral neurons. Neurosci Lett 144: 215–220.
• Ariano MA, Wang J, Noblett KL, Larson ER, Sibley DR. 1997. Cellular distribution of the rat D1B receptor in central nervous system using anti-receptor antisera. Brain Res 746: 141–150.
• Arnsten AF, Goldman-Rakic PS. 1985. Alpha 2-adrenergic mechanisms in prefrontal cortex associated with cognitive decline in aged nonhuman primates. Science 230: 1273–1276.
• Arnsten AF, Steere JC, Hunt RD. 1996. The contribution of alpha 2-noradrenergic mechanisms of prefrontal cortical cognitive function. Potential significance for attention-deficit hyperactivity disorder. Arch Gen Psychiatry 53: 448–455.
• Aronica E, Gorter JA, Ijlst-Keizers H, Rozemuller AJ, Yankaya B, et al. 2003. Expression and functional role of mGluR3 and mGluR5 in human astrocytes and glioma cells: Opposite regulation of glutamate transporter proteins. Eur J Neurosci 17: 2106–2118.
• Arora RC, Meltzer HY. 1991. Serotonin2 (5-HT2) receptor binding in the frontal cortex of schizophrenic patients. J Neural Transm Gen Sect.;85(1): 19–29.
• Aston-Jones G, Rajkowski J, Cohen J. 1999. Role of locus coeruleus in attention and behavioral flexibility. Biol Psychiatry 46: 1309–1320.
• Asztely F, Gustafsson B. 1996. Ionotropic glutamate receptors. Their possible role in the expression of hippocampal synaptic plasticity. Mol Neurobiol 12: 1–11.
• Bai J, He F, Novikova SI, Undie AS, Dracheva S, et al. 2004. Abnormalities in the dopamine system in schizophrenia may lie in altered levels of dopamine receptor-interacting proteins. Biol Psychiatry 56: 427–440.
• Baracskay KL, Haroutunian V, Meador-Woodruff JH. 2006. Dopamine receptor signaling molecules are altered in elderly schizophrenic cortex. Synapse 60: 271–279.
• Baumeister AA, Francis JL. 2002. Historical development of the dopamine hypothesis of schizophrenia. J Hist Neurosci 11: 265–277.
• Benes FM, Berretta S. 2001. GABAergic interneurons: Implications for understanding schizophrenia and bipolar disorder. Neuropsychopharmacology 25: 1–27.
• Benes FM, Khan Y, Vincent SL, Wickramasinghe R. 1996a. Differences in the subregional and cellular distribution of GABAA receptor binding in the hippocampal formation of schizophrenic brain. Synapse 22: 338–349.
• Benes FM, McSparren J, Bird ED, SanGiovanni JP, Vincent SL. 1991. Deficits in small interneurons in prefrontal and cingulate cortices of schizophrenic and schizoaffective patients. Arch Gen Psychiatry 48: 996–1001.
• Benes FM, Todtenkopf MS, Kostoulakos P. 2001. GluR5,6,7 subunit immunoreactivity on apical pyramidal cell dendrites in hippocampus of schizophrenics and manic depressives. Hippocampus 11: 482–491.
• Benes FM, Vincent SL, Alsterberg G, Bird ED, SanGiovanni JP. 1992. Increased GABAA receptor binding in superficial layers of cingulate cortex in schizophrenics. J Neurosci 12: 924–929.
• Benes FM, Vincent SL, Marie A, Khan Y. 1996b. Up-regulation of GABAA receptor binding on neurons of the prefrontal cortex in schizophrenic subjects. Neuroscience 75: 1021–1031.
• Benes FM, Wickramasinghe R, Vincent SL, Khan Y, Todtenkopf M. 1997. Uncoupling of GABA(A) and benzodiazepine receptor binding activity in the hippocampal formation of schizophrenic brain. Brain Res 755: 121–129.
• Beneyto M, Kristiansen LV, Oni-Orisan A, McCullumsmith RE, Meador-Woodruff JH. 2007. Abnormal glutamate receptor expression in the medial temporal lobe in schizophrenia and mood disorders. Neuropsychopharmacology 32: 1888–1902.
• Beneyto M, Meador-Woodruff JH. 2006. Lamina-specific abnormalities of AMPA receptor trafficking and signaling molecule transcripts in the prefrontal cortex in schizophrenia. Synapse 60: 585–598.
• Bennett JP Jr, Enna SJ, Bylund DB, Gillin JC, Wyatt RJ, Snyder SH. 1979. Neurotransmitter receptors in frontal cortex of schizophrenics. Arch Gen Psychiatry 36(9): 927–934.
• Berger PA. 1981. Biochemistry and the schizophrenia. Old concepts and new hypothesis. J Nerv Ment Dis 169: 90–99.
• Bergson C, Mrzljak L, Smiley JF, Pappy M, Levenson R, et al. 1995. Regional, cellular, and subcellular variations in the distribution of D1 and D5 dopamine receptors in primate brain. J Neurosci 15: 7821–7836.
• Bochet P, Rossier J. 1993. Molecular biology of excitatory amino acid receptors: Subtypes and subunits. Exs 63: 224–233.
• Bockaert J. 1991. Coupling of receptors to G proteins, pharmacological implications. Therapie 46: 413–420.
• Bodor AL, Katona I, Nyiri G, Mackie K, Ledent C, et al. 2005. Endocannabinoid signaling in rat somatosensory cortex: Laminar differences and involvement of specific interneuron types. J Neurosci 25: 6845–6856.
• Booze RM, Crisostomo EA, Davis JN. 1993. Beta-adrenergic receptors in the hippocampal and retrohippocampal regions of rats and guinea pigs: Autoradiographic and immunohistochemical studies. Synapse 13: 206–214.
• Bortolozzi A, Diaz-Mataix L, Scorza MC, Celada P, Artigas F. 2005. The activation of 5-HT receptors in prefrontal cortex enhances dopaminergic activity. J Neurochem 95: 1597–1607.
• Bouchard P, Quirion R. 1997. [3H]1,3-di(2-tolyl)guanidine and [3H](+)pentazocine binding sites in the rat brain: Autoradiographic visualization of the putative sigma1 and sigma2 receptor subtypes. Neuroscience 76: 467–477.
• Bowden NA, Scott RJ, Tooney PA. 2007. Altered expression of regulator of G-protein signalling 4 (RGS4) mRNA in the superior temporal gyrus in schizophrenia. Schizophr Res 89: 165–168.
• Bowen WD. 2000. Sigma receptors: Recent advances and new clinical potentials. Pharm Acta Helv 74: 211–218.
• Bradley J, Carter SR, Rao VR, Wang J, Finkbeiner S. 2006. Splice variants of the NR1 subunit differentially induce NMDA receptor-dependent gene expression. J Neurosci 26: 1065–1076.
• Braithwaite SP, Xia H, Malenka RC. 2002. Differential roles for NSF and GRIP/ABP in AMPA receptor cycling. Proc Natl Acad Sci USA 99: 7096–7101.
• Brann MR, Ellis J, Jorgensen H, Hill-Eubanks D, Jones SV. 1993. Muscarinic acetylcholine receptor subtypes: Localization and structure/function. Prog Brain Res 98: 121–127.
• Breese CR, Freedman R, Leonard SS. 1995. Glutamate receptor subtype expression in human postmortem brain tissue from schizophrenics and alcohol abusers. Brain Res 674: 82–90.
• Breese CR, Lee MJ, Adams CE, Sullivan B, Logel J, et al. 2000. Abnormal regulation of high affinity nicotinic receptors in subjects with schizophrenia. Neuropsychopharmacology 23: 351–364.
• Breese CR, Leonard SS. 1993. Glutamate receptor subtype expression in human postmortem brain. J Mol Neurosci 4: 263–275.
• Breivogel CS, Griffin G, Di Marzo V, Martin BR. 2001. Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Mol Pharmacol 60: 155–163.
• Brose N, Gasic GP, Vetter DE, Sullivan JM, Heinemann SF. 1993. Protein chemical characterization and immunocytochemical localization of the NMDA receptor subunit NMDA R1. J Biol Chem 268: 22663–22671.
• Brown RE, Stevens DR, Haas HL. 2001. The physiology of brain histamine. Prog Neurobiol 63: 637–672.
• Brumwell CL, Johnson JL, Jacob MH. 2002. Extrasynaptic alpha 7-nicotinic acetylcholine receptor expression in developing neurons is regulated by inputs, targets, and activity. J Neurosci 22: 8101–8109.
• Burnet PW, Eastwood SL, Harrison PJ. 1996. 5-HT1A and 5-HT2A receptor mRNAs and binding site densities are differentially altered in schizophrenia. Neuropsychopharmacology 15: 442–455.
• Burnet PW, Eastwood SL, Harrison PJ. 1997. [3H]WAY-100635 for 5-HT1A receptor autoradiography in human brain: a comparison with [3H]8-OH-DPAT and demonstration of increased binding in the frontal cortex in schizophrenia. Neurochem Int 30(6): 565–574.
• Burnet PW, Harrison PJ. 2000. Substance P (NK1) receptors in the cingulate cortex in unipolar and bipolar mood disorder and schizophrenia. Biol Psychiatry 1;47(1): 80–83.
• Bymaster FP, McKinzie DL, Felder CC, Wess J. 2003. Use of M1-M5 muscarinic receptor knockout mice as novel tools to delineate the physiological roles of the muscarinic cholinergic system. Neurochem Res 28: 437–442.
• Cadet P, Mantione KJ, Stefano GB. 2003. Molecular identification and functional expression of mu 3, a novel alternatively spliced variant of the human mu opiate receptor gene. J Immunol 170: 5118–5123.
• Cai C, Li H, Rivera C, Keinanen K. 2006. Interaction between SAP97 and PSD-95, two Maguk proteins involved in synaptic trafficking of AMPA receptors. J Biol Chem 281: 4267–4273.
• Cao W, Luttrell LM, Medvedev AV, Pierce KL, Daniel KW, et al. 2000. Direct binding of activated c-Src to the beta 3-adrenergic receptor is required for MAP kinase activation. J Biol Chem 275: 38131–38134.
• Carletti R, Corsi M, Melotto S, Caberlotto L. 2005. Down-regulation of amygdala preprotachykinin A mRNA but not 3H-SP receptor binding sites in subjects affected by mood disorders and schizophrenia. Eur J Neurosci 21: 1712–1718.
• Carli M, Baviera M, Invernizzi RW, Balducci C. 2006. Dissociable contribution of 5-HT1A and 5-HT2A receptors in the medial prefrontal cortex to different aspects of executive control such as impulsivity and compulsive perseveration in rats. Neuropsychopharmacology 31: 757–767.
• Cartmell J, Schoepp DD. 2000. Regulation of neurotransmitter release by metabotropic glutamate receptors. J Neurochem 75: 889–907.
• Castensson A, Emilsson L, Sundberg R, Jazin E. 2003. Decrease of serotonin receptor 2C in schizophrenia brains identified by high-resolution mRNA expression analysis. Biol Psychiatry 54: 1212–1221.
• Chahl LA. 2006. Tachykinins and neuropsychiatric disorders. Curr Drug Targets 7: 993–1003.
• Chang Y, Wang R, Barot S, Weiss DS. 1996. Stoichiometry of a recombinant GABAA receptor. J Neurosci 16: 5415–5424.
• Chen L, Huang LY. 1992. Protein kinase C reduces Mg2+ block of NMDA-receptor channels as a mechanism of modulation. Nature 356: 521–523.
• Childers SR, Pacheco MA, Bennett BA, Edwards TA, Hampson RE, et al. 1993. Cannabinoid receptors: G-protein-mediated signal transduction mechanisms. Biochem Soc Symp 59: 27–50.
• Choi WS, Machida CA, Ronnekleiv OK. 1995. Distribution of dopamine D1, D2, and D5 receptor mRNAs in the monkey brain: Ribonuclease protection assay analysis. Brain Res Mol Brain Res 31: 86–94.
• Church J, Fletcher EJ. 1995. Blockade by sigma site ligands of high voltage-activated Ca2+ channels in rat and mouse cultured hippocampal pyramidal neurones. Br J Pharmacol 116: 2801–2810.
• Civantos Calzada B, Aleixandre de Artinano A. 2001. Alpha-adrenoceptor subtypes. Pharmacol Res 44: 195–208.
• Clark DA, Mancama D, Kerwin RW, Arranz MJ. 2006. Expression of the alpha1A-adrenergic receptor in schizophrenia. Neurosci Lett 401: 248–251.
• Clark JA, Liu L, Price M, Hersh B, Edelson M, et al. 1989. Kappa opiate receptor multiplicity: Evidence for two U50,488-sensitive kappa 1 subtypes and a novel kappa 3 subtype. J Pharmacol Exp Ther 251: 461–468.
• Clarke PB, Pert A. 1985. Autoradiographic evidence for nicotine receptors on nigrostriatal and mesolimbic dopaminergic neurons. Brain Res 348: 355–358.
• Clinton SM, Abelson S, Haroutunian V, Davis KL, Meador-Woodruff JH. 2004. Neurofilament subunit protein abnormalities in the thalamus in shizophrenia. Thalamus Relat Syst 2: 265–272.
• Clinton SM, Haroutunian V, Davis KL, Meador-Woodruff JH. 2003. Altered transcript expression of NMDA receptor-associated postsynaptic proteins in the thalamus of subjects with schizophrenia. Am J Psychiatry 160: 1100–1109.
• Clinton SM, Haroutunian V, Meador-Woodruff JH. 2006. Up-regulation of NMDA receptor subunit and post-synaptic density protein expression in the thalamus of elderly patients with schizophrenia. J Neurochem 98(4): 1114–1125.
• Clinton SM, Ibrahim HM, Frey KA, Davis KL, Haroutunian V, et al. 2005. Dopaminergic abnormalities in select thalamic nuclei in schizophrenia: Involvement of the intracellular signal integrating proteins calcyon and spinophilin. Am J Psychiatry 162: 1859–1871.
• Clinton SM, Meador-Woodruff JH. 2004a. Abnormalities of the NMDA receptor and associated intracellular molecules in the thalamus in schizophrenia and bipolar disorder. Neuropsychopharmacology 29: 1353–1362.
• Clinton SM, Meador-Woodruff JH. 2004b. Thalamic dysfunction in schizophrenia: Neurochemical, neuropathological, and in vivo imaging abnormalities. Schizophr Res 69: 237–253.
• Collinge J, Curtis D. 1991. Decreased hippocampal expression of a glutamate receptor gene in schizophrenia. Br J Psychiatry 159: 857–859.
• Collins MO, Husi H, Yu L, Brandon JM, Anderson CN, et al. 2006. Molecular characterization and comparison of the components and multiprotein complexes in the postsynaptic proteome. J Neurochem : 97(Suppl. 1): 16–23.
• Conn PJ, Pin JP. 1997. Pharmacology and functions of metabotropic glutamate receptors. Annu Rev Pharmacol Toxicol 37: 205–237.
• Conti F, Barbaresi P, Melone M, Ducati A. 1999. Neuronal and glial localization of NR1 and NR2A/B subunits of the NMDA receptor in the human cerebral cortex. Cereb Cortex 9: 110–120.
• Court J, Spurden D, Lloyd S, McKeith I, Ballard C, et al. 1999. Neuronal nicotinic receptors in dementia with Lewy bodies and schizophrenia: Alpha-bungarotoxin and nicotine binding in the thalamus. J Neurochem 73: 1590–1597.
• Court JA, Piggott MA, Lloyd S, Cookson N, Ballard CG, et al. 2000. Nicotine binding in human striatum: Elevation in schizophrenia and reductions in dementia with Lewy bodies, Parkinson’s disease and Alzheimer’s disease and in relation to neuroleptic medication. Neuroscience 98: 79–87.
• Coussen F, Mulle C. 2006. Kainate receptor-interacting proteins and membrane trafficking. Biochem Soc Trans 34: 927–930.
• Coussen F, Perrais D, Jaskolski F, Sachidhanandam S, Normand E, et al. 2005. Co-assembly of two GluR6 kainate receptor splice variants within a functional protein complex. Neuron 47: 555–566.
• Coutinho V, Knopfel T. 2002. Metabotropic glutamate receptors: Electrical and chemical signaling properties. Neuroscientist 8: 551–561.
• Coyle JT. 2006. Glutamate and schizophrenia: Beyond the dopamine hypothesis. Cell Mol Neurobiol 26: 365–384.
• Coyle JT, Tsai G, Goff D. 2003. Converging evidence of NMDA receptor hypofunction in the pathophysiology of schizophrenia. Ann NY Acad Sci 1003: 318–327.
• Crichton-Browne J. 1879. On the weight of the brain and its components in the insane. Brain 2: 42–67.
• Crook JM, Dean B, Pavey G, Copolov D. 1999. The binding of [3H]AF-DX 384 is reduced in the caudate-putamen of subjects with schizophrenia. Life Sci 64: 1761–1771.
• Crook JM, Tomaskovic-Crook E, Copolov DL, Dean B. 2000. Decreased muscarinic receptor binding in subjects with schizophrenia: A study of the human hippocampal formation. Biol Psychiatry 48: 381–388.
• Crook JM, Tomaskovic-Crook E, Copolov DL, Dean B. 2001. Low muscarinic receptor binding in prefrontal cortex from subjects with schizophrenia: A study of Brodmann’s areas 8, 9, 10, and 46 and the effects of neuroleptic drug treatment. Am J Psychiatry 158: 918–925.
• Cruz DA, Eggan SM, Azmitia EC, Lewis DA. 2004. Serotonin1A receptors at the axon initial segment of prefrontal pyramidal neurons in schizophrenia. Am J Psychiatry 161: 739–742.
• Cull-Candy S, Brickley S, Farrant M. 2001. NMDA receptor subunits: Diversity, development and disease. Curr Opin Neurobiol 11: 327–335.
• Dalack GW, Becks L, Hill E, Pomerleau OF, Meador-Woodruff JH. 1999. Nicotine withdrawal and psychiatric symptoms in cigarette smokers with schizophrenia. Neuropsychopharmacology 21: 195–202.
• Dalack GW, Healy DJ, Meador-Woodruff JH. 1998. Nicotine dependence in schizophrenia: Clinical phenomena and laboratory findings. Am J Psychiatry 155: 1490–1501.
• Dani JA, Bertrand D. 2007. Nicotinic acetylcholine receptors and nicotinic cholinergic mechanisms of the central nervous system. Annu Rev Pharmacol Toxicol 47: 699–729.
• Davis KL, Kahn RS, Ko G, Davidson M. 1991. Dopamine in schizophrenia: A review and reconceptualization. Am J Psychiatry 148: 1474–1486.
• De Luca V, Likhodi O, Van Tol HH, Kennedy JL, Wong AH. 2006. Regulation of alpha7-nicotinic receptor subunit and alpha7-like gene expression in the prefrontal cortex of patients with bipolar disorder and schizophrenia. Acta Psychiatr Scand 114: 211–215.
• Deakin JF, Slater P, Simpson MD, Gilchrist AC, Skan WJ, et al. 1989. Frontal cortical and left temporal glutamatergic dysfunction in schizophrenia. J Neurochem 52: 1781–1786.
• Dean B. 2003. [3H]RX 821002 in human dorsolateral prefrontal cortex: No changes in postmortem tissue from subjects with schizophrenia. Psychiatry Res 119: 25–31.
• Dean B, Crook JM, Opeskin K, Hill C, Keks N, et al. 1996. The density of muscarinic M1 receptors is decreased in the caudate-putamen of subjects with schizophrenia. Mol Psychiatry 1: 54–58.
• Dean B, Hayes W, Hill C, Copolov D. 1998. Decreased serotonin2A receptors in Brodmann's area 9 from schizophrenic subjects. A pathological or pharmacological phenomenon? Mol Chem Neuropathol 34(2-3): 133–145.
• Dean B, Tomaskovic-Crook E, Opeskin K, Keks N, Copolov D. 1999. No change in the density of the serotonin1A receptor, the serotonin4 receptor or the serotonin transporter in the dorsolateral prefrontal cortex from subjects with schizophrenia. Neurochem Int. 34(2):109–15.
• Dean B, Hussain T, Hayes W, Scarr E, Kitsoulis S, et al. 1999a. Changes in serotonin2A and GABA(A) receptors in schizophrenia: Studies on the human dorsolateral prefrontal cortex. J Neurochem 72: 1593–1599.
• Dean B, McLeod M, Keriakous D, McKenzie J, Scarr E. 2002. Decreased muscarinic1 receptors in the dorsolateral prefrontal cortex of subjects with schizophrenia. Mol Psychiatry 7: 1083–1091.
• Dean B, Pavey G, Scarr E, Goeringer K, Copolov DL. 2004. Measurement of dopamine D2-like receptors in postmortem CNS and pituitary: Differential regional changes in schizophrenia. Life Sci 74: 3115–3131.
• Dean B, Pavey G, Thomas D, Scarr E. 2006. Cortical serotonin7, 1D and 1F receptors: Effects of schazophrenia, suicide and antipsychotic drug treatment. Schizophr Res: 88: 265–274.
• Dean B, Scarr E, Bradbury R, Copolov D. 1999b. Decreased hippocampal (CA3) NMDA receptors in schizophrenia. Synapse 32: 67–69.
• Dean B, Scarr E, McLeod M. 2005. Changes in hippocampal GABAA receptor subunit composition in bipolar 1 disorder. Brain Res Mol Brain Res 138(2): 145–155.
• Dean B, Sundram S, Bradbury R, Scarr E, Copolov D. 2001. Studies on [3H]CP-55940 binding in the human central nervous system: Regional specific changes in density of cannabinoid-1 receptors associated with schizophrenia and cannabis use. Neuroscience 103: 9–15.
• DeBock F, Kurz J, Azad SC, Parsons CG, Hapfelmeier G, et al. 2003. Alpha2-adrenoreceptor activation inhibits LTP and LTD in the basolateral amygdala: Involvement of Gi/o-protein-mediated modulation of Ca2+-channels and inwardly rectifying K+-channels in LTD. Eur J Neurosci 17: 1411–1424.
• Deng C, Huang XF. 2005. Decreased density of muscarinic receptors in the superior temporal gyrusin schizophrenia. J Neurosci Res 81: 883–890.
• Deng C, Huang XF. 2006. Increased density of GABAA receptors in the superior temporal gyrus in schizophrenia. Exp Brain Res 168: 587–590.
• Derbez AE, Mody RM, Werling LL. 2002. Sigma(2)-receptor regulation of dopamine transporter via activation of protein kinase C. J Pharmacol Exp Ther 301: 306–314.
• Doreulee N, Yanovsky Y, Flagmeyer I, Stevens DR, Haas HL, et al. 2001. Histamine H(3) receptors depress synaptic transmission in the corticostriatal pathway. Neuropharmacology 40: 106–113.
• Dracheva S, Marras SA, Elhakem SL, Kramer FR, Davis KL, et al. 2001. N-methyl-D-aspartic acid receptor expression in the dorsolateral prefrontal cortex of elderly patients with schizophrenia. Am J Psychiatry 158: 1400–1410.
• Dracheva S, Elhakem SL, Marcus SM, Siever LJ, McGurk SR, Haroutunian V. 2003. RNA editing and alternative splicing of human serotonin 2C receptor in schizophrenia. J Neurochem 87(6): 1402–1412.
• Dracheva S, McGurk SR, Haroutunian V. 2005. mRNA expression of AMPA receptors and AMPA receptor binding proteins in the cerebral cortex of elderly schizophrenics. J Neurosci Res 79: 868–878.
• Duman RS, Heninger GR, Nestler EJ. 1994. Molecular psychiatry. Adaptations of receptor-coupled signal transduction pathways underlying stress- and drug-induced neural plasticity. J Nerv Ment Dis 182: 692–700.
• Durany N, Zochling R, Boissl KW, Paulus W, Ransmayr G, et al. 2000. Human post-mortem striatal alpha4beta2 nicotinic acetylcholine receptor density in schizophrenia and Parkinson’s syndrome. Neurosci Lett 287: 109–112.
• Dursun SM, Kutcher S. 1999. Smoking, nicotine and psychiatric disorders: Evidence for therapeutic role, controversies and implications for future research. Med Hypotheses 52: 101–109.
• East SZ, Burnet PW, Kerwin RW, Harrison PJ. 2002. An RT-PCR study of 5-HT(6) and 5-HT(7) receptor mRNAs in the hippocampal formation and prefrontal cortex in schizophrenia. Schizophr Res 57: 15–26.
• Eastwood SL, Burnet PW, Harrison PJ. 1997a. GluR2 glutamate receptor subunit flip and flop isoforms are decreased in the hippocampal formation in schizophrenia: A reverse transcriptase-polymerase chain reaction (RT-PCR) study. Brain Res Mol Brain Res 44: 92–98.
• Eastwood SL, Kerwin RW, Harrison PJ. 1997b. Immunoautoradiographic evidence for a loss of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate-preferring non-N-methyl-D-aspartate glutamate receptors within the medial temporal lobe in schizophrenia. Biol Psychiatry 41: 636–643.
• Eastwood SL, McDonald B, Burnet PW, Beckwith JP, Kerwin RW, et al. 1995. Decreased expression of mRNAs encoding non-NMDA glutamate receptors GluR1 and GluR2 in medial temporal lobe neurons in schizophrenia. Brain Res Mol Brain Res 29: 211–223.
• Egan CT, Herrick-Davis K, Teitler M. 1998. Creation of a constitutively activated state of the 5-hydroxytryptamine2A receptor by site-directed mutagenesis: Inverse agonist activity of antipsychotic drugs. J Pharmacol Exp Ther 286: 85–90.
• Eggan SM, Lewis DA. 2007. Immunocytochemical distribution of the cannabinoid CB1 receptor in the primate neocortex: A regional and laminar analysis. Cereb Cortex 17: 175–191.
• Ehlers MD, Fung ET, O’Brien RJ, Huganir RL. 1998. Splice variant-specific interaction of the NMDA receptor subunit NR1 with neuronal intermediate filaments. J Neurosci 18: 720–730.
• Eitan S, Bryant CD, Saliminejad N, Yang YC, Vojdani E, et al. 2003. Brain region-specific mechanisms for acute morphine-induced mitogen-activated protein kinase modulation and distinct patterns of activation during analgesic tolerance and locomotor sensitization. J Neurosci 23: 8360–8369.
• Ellison GD, Eison MS. 1983. Continuous amphetamine intoxication: An animal model of the acute psychotic episode. Psychol Med 13: 751–761.
• Emamian ES, Karayiorgou M, Gogos JA. 2004. Decreased phosphorylation of NMDA receptor type 1 at serine 897 in brains of patients with Schizophrenia. J Neurosci 24: 1561–1564.
• Enz R, Cutting GR. 1998. Molecular composition of GABAC receptors. Vision Res 38: 1431–1441.
• Erdely HA, Lahti RA, Lopez MB, Myers CS, Roberts RC, et al. 2004. Regional expression of RGS4 mRNA in human brain. Eur J Neurosci 19: 3125–3128.
• Erdely HA, Tamminga CA, Roberts RC, Vogel MW. 2006. Regional alterations in RGS4 protein in schizophrenia. Synapse 59: 472–479.
• Erecinska M, Silver IA. 1990. Metabolism and role of glutamate in mammalian brain. Prog Neurobiol 35: 245–296.
• Esbenshade TA, Fox GB, Cowart MD. 2006. Histamine H3 receptor antagonists: Preclinical promise for treating obesity and cognitive disorders. Mol Interv 6: 77–88, 59.
• Evans CJ, Keith DE Jr, Morrison H, Magendzo K, Edwards RH. 1992. Cloning of a delta opioid receptor by functional expression. Science 258: 1952–1955.
• Fang L, Knapp RJ, Horvath R, Matsunaga TO, Haaseth RC, et al. 1994. Characterization of [3H]naltrindole binding to delta opioid receptors in mouse brain and mouse vas deferens: Evidence for delta opioid receptor heterogeneity. J Pharmacol Exp Ther 268: 836–846.
• Felder CC, Joyce KE, Briley EM, Mansouri J, Mackie K, et al. 1995. Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol Pharmacol 48: 443–450.
• Filip M, Frankowska M, Zaniewska M, Golda A, Przegalinski E. 2005. The serotonergic system and its role in cocaine addiction. Pharmacol Rep 57: 685–700.
• Filloux F, Dawson TM, Wamsley JK. 1988. Localization of nigrostriatal dopamine receptor subtypes and adenylate cyclase. Brain Res Bull 20: 447–459.
• Fisher JL. 2004. The alpha 1 and alpha 6 subunit subtypes of the mammalian GABA(A) receptor confer distinct channel gating kinetics. J Physiol 561: 433–448.
• Fisher RS, Levine MS, Sibley DR, Ariano MA. 1994. D2 dopamine receptor protein location: Golgi impregnation-gold toned and ultrastructural analysis of the rat neostriatum. J Neurosci Res 38: 551–564.
• Freedman R, Hall M, Adler LE, Leonard S. 1995. Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia. Biol Psychiatry 38: 22–33.
• Fremeau RT Jr, Duncan GE, Fornaretto MG, Dearry A, Gingrich JA, et al. 1991. Localization of D1 dopamine receptor mRNA in brain supports a role in cognitive, affective, and neuroendocrine aspects of dopaminergic neurotransmission. Proc Natl Acad Sci USA 88: 3772–3776.
• Fritschy JM, Brunig I. 2003. Formation and plasticity of GABAergic synapses: Physiological mechanisms and pathophysiological implications. Pharmacol Ther 98: 299–323.
• Fritschy JM, Mohler H. 1995. GABAA-receptor heterogeneity in the adult rat brain: Differential regional and cellular distribution of seven major subunits. J Comp Neurol 359: 154–194.
• Gaimarri A, Moretti M, Riganti L, Zanardi A, Clementi F, et al. 2007. Regulation of neuronal nicotinic receptor traffic and expression. Brain Res Rev: 55: 134–143.
• Gao XM, Sakai K, Roberts RC, Conley RR, Dean B, et al. 2000. Ionotropic glutamate receptors and expression of N-methyl-D-aspartate receptor subunits in subregions of human hippocampus: Effects of schizophrenia. Am J Psychiatry 157: 1141–1149.
• Garey LJ, Von Bussmann KA, Hirsch SR. 2006. Decreased numerical density of kainate receptor-positive neurons in the orbitofrontal cortex of chronic schizophrenics. Exp Brain Res. 173(2): 234–42.
• Gasic GP, Heinemann S. 1991. Receptors coupled to ionic channels: The glutamate receptor family. Curr Opin Neurobiol 1: 20–26.
• Gegelashvili G, Dehnes Y, Danbolt NC, Schousboe A. 2000. The high-affinity glutamate transporters GLT1, GLAST, and EAAT4 are regulated via different signalling mechanisms. Neurochem Int 37: 163–170.
• Geldwert D, Norris JM, Feldman IG, Schulman JJ, Joyce MP, et al. 2006. Dopamine presynaptically and heterogeneously modulates nucleus accumbens medium-spiny neuron GABA synapses in vitro. BMC Neurosci 7: 53.
• Gerard CM, Mollereau C, Vassart G, Parmentier M. 1991. Molecular cloning of a human cannabinoid receptor which is also expressed in testis. Biochem J 279: (Pt 1)129–134.
• Gingrich JA, Dearry A, Falardeau P, Bates MD, Fremeau RT Jr, et al. 1992. Location and molecular cloning of D1 dopamine receptor. Neurochem Int 20(Suppl.): 9S–15S.
• Goldsmith SK, Shapiro RM, Joyce JN. 1997. Disrupted pattern of D2 dopamine receptors in the temporal lobe in schizophrenia. A postmortem study. Arch Gen Psychiatry 54: 649–658.
• Gong JP, Onaivi ES, Ishiguro H, Liu QR, Tagliaferro PA, et al. 2006. Cannabinoid CB2 receptors: Immunohistochemical localization in rat brain. Brain Res 1071: 10–23.
• Gotti C, Clementi F. 2004. Neuronal nicotinic receptors: From structure to pathology. Prog Neurobiol 74: 363–396.
• Gotti C, Moretti M, Gaimarri A, Zanardi A, Clementi F, et al. 2007. Heterogeneity and complexity of native brain nicotinic receptors. Biochem Pharmacol 74: 1102–1111.
• Gotti C, Zoli M, Clementi F. 2006. Brain nicotinic acetylcholine receptors: Native subtypes and their relevance. Trends Pharmacol Sci 27: 482–491.
• Gray L, Scarr E, Dean B. 2006. Serotonin 1a receptor and associated G-protein activation in schizophrenia and bipolar disorder. Psychiatry Res 143(2-3): 111–120.
• Greene JG. 2006. Gene expression profiles of brain dopamine neurons and relevance to neuropsychiatric disease. J Physiol 575: 411–416.
• Grevel J, Yu V, Sadee W. 1985. Characterization of a labile naloxone binding site (lambda site) in rat brain. J Neurochem 44: 1647–1656.
• Grueter BA, Winder DG. 2005. Group II and III metabotropic glutamate receptors suppress excitatory synaptic transmission in the dorsolateral bed nucleus of the stria terminalis. Neuropsychopharmacology 30: 1302–1311.
• Guan ZZ, Zhang X, Blennow K, Nordberg A. 1999. Decreased protein level of nicotinic receptor alpha7 subunit in the frontal cortex from schizophrenic brain. Neuroreport 10: 1779–1782.
• Guitart X, Codony X, Monroy X. 2004. Sigma receptors: Biology and therapeutic potential. Psychopharmacology (Berl) 174: 301–319.
• Gupta DS, McCullumsmith RE, Beneyto M, Haroutunian V, Davis KL, et al. 2005. Metabotropic glutamate receptor protein expression in the prefrontal cortex and striatum in schizophrenia. Synapse 57: 123–131.
• Gurevich EV, Bordelon Y, Shapiro RM, Arnold SE, Gur RE, et al. 1997. Mesolimbic dopamine D3 receptors and use of antipsychotics in patients with schizophrenia. A postmortem study. Arch Gen Psychiatry 54: 225–232.
• Gurevich EV, Joyce JN. 1997. Alterations in the cortical serotonergic system in schizophrenia: A postmortem study. Biol Psychiatry 42(7): 529–545.
• Haak LL. 1999. Metabotropic glutamate receptor modulation of glutamate responses in the suprachiasmatic nucleus. J Neurophysiol 81: 1308–1317.
• Haber SN. 1986. Neurotransmitters in the human and nonhuman primate basal ganglia. Hum Neurobiol 5: 159–168.
• Hadcock JR, Port JD, Gelman MS, Malbon CC. 1992. Cross-talk between tyrosine kinase and G-protein-linked receptors. Phosphorylation of beta 2-adrenergic receptors in response to insulin. J Biol Chem 267: 26017–26022.
• Hakak Y, Walker JR, Li C, Wong WH, Davis KL, et al. 2001. Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia. Proc Natl Acad Sci USA 98: 4746–4751.
• Hall RA. 2004. Beta-adrenergic receptors and their interacting proteins. Semin Cell Dev Biol 15: 281–288.
• Harrington KA, Augood SJ, Faull RL, McKenna PJ, Emson PC. 1995. Dopamine D1 receptor, D2 receptor, proenkephalin A and substance P gene expression in the caudate nucleus of control and schizophrenic tissue: A quantitative cellular in situ hybridisation study. Brain Res Mol Brain Res 33: 333–342.
• Harrison JK, Pearson WR, Lynch KR. 1991. Molecular characterization of alpha 1- and alpha 2-adrenoceptors. Trends Pharmacol Sci 12: 62–67.
• Harrison PJ, Law AJ, Eastwood SL. 2003. Glutamate receptors and transporters in the hippocampus in schizophrenia. Ann NY Acad Sci 1003: 94–101.
• Hartman DS, Civelli O. 1996. Molecular attributes of dopamine receptors: New potential for antipsychotic drug development. Ann Med 28: 211–219.
• Hashimoto T, Kitamura N, Kajimoto Y, Shirai Y, Shirakawa O, Mita T, Nishino N, Tanaka C. 1993. Differential changes in serotonin 5-HT1A and 5-HT2 receptor binding in patients with chronic schizophrenia. Psychopharmacology 112(1 Suppl): S35–9. Review.
• Hashimoto T, Arion D, Unger T, Maldonado-Aviles JG, Morris HM, et al. 2007. Alterations in GABA-related transcriptome in the dorsolateral prefrontal cortex of subjects with schizophrenia. Mol Psychiatry 1: 1.
• Hashimoto T, Nishino N, Nakai H, Tanaka C. 1991. Increase in serotonin 5-HT1A receptors in prefrontal and temporal cortices of brains from patients with chronic schizophrenia. Life Sci 48: 355–363.
• He J, Xu J, Castleberry AM, Lau AG, Hall RA. 2002. Glycosylation of beta(1)-adrenergic receptors regulates receptor surface expression and dimerization. Biochem Biophys Res Commun 297: 565–572.
• Healy DJ, Haroutunian V, Powchik P, Davidson M, Davis KL, et al. 1998. AMPA receptor binding and subunit mRNA expression in prefrontal cortex and striatum of elderly schizophrenics. Neuropsychopharmacology 19: 278–286.
• Helmeste DM, Tang SW, Bunney WE Jr, Potkin SG, Jones EG. 1996. Decrease in sigma but no increase in striatal dopamine D4 sites in schizophrenic brains. Eur J Pharmacol 314: R3–R5.
• Hemby SE, Ginsberg SD, Brunk B, Arnold SE, Trojanowski JQ, et al. 2002. Gene expression profile for schizophrenia: Discrete neuron transcription patterns in the entorhinal cortex. Arch Gen Psychiatry 59: 631–640.
• Henneberry RC. 1992. Cloning of the genes for excitatory amino acid receptors. Bioessays 14: 465–471.
• Herkenham M, Lynn AB, Johnson MR, Melvin LS, de Costa BR, et al. 1991. Characterization and localization of cannabinoid receptors in rat brain: A quantitative in vitro autoradiographic study. J Neurosci 11: 563–583.
• Hermans E, Challiss RA. 2001. Structural, signalling and regulatory properties of the group I metabotropic glutamate receptors: Prototypic family C G-protein-coupled receptors. Biochem J 359: 465–484.
• Hernandez I, Sokolov BP. 2000. Abnormalities in 5-HT2A receptor mRNA expression in frontal cortex of chronic elderly schizophrenics with varying histories of neuroleptic treatment. J Neurosci Res 59: 218–225.
• Hess EJ, Bracha HS, Kleinman JE, Creese I. 1987. Dopamine receptor subtype imbalance in schizophrenia. Life Sci 40: 1487–1497.
• Hillman KL, Doze VA, Porter JE. 2005. Functional characterization of the beta-adrenergic receptor subtypes expressed by CA1 pyramidal cells in the rat hippocampus. J Pharmacol Exp Ther 314: 561–567.
• Hirbec H, Francis JC, Lauri SE, Braithwaite SP, Coussen F, et al. 2003. Rapid and differential regulation of AMPA and kainate receptors at hippocampal mossy fibre synapses by PICK1 and GRIP. Neuron 37: 625–638.
• Hoffman AF, Lupica CR. 2000. Mechanisms of cannabinoid inhibition of GABA(A) synaptic transmission in the hippocampus. J Neurosci 20: 2470–2479.
• Hoogland TM, Saggau P. 2004. Facilitation of L-type Ca2+ channels in dendritic spines by activation of beta2 adrenergic receptors. J Neurosci 24: 8416–8427.
• Hu LA, Tang Y, Miller WE, Cong M, Lau AG, et al. 2000. beta 1-adrenergic receptor association with PSD-95. Inhibition of receptor internalization and facilitation of beta 1-adrenergic receptor interaction with N-methyl-D-aspartate receptors. J Biol Chem 275: 38659–38666.
• Huang M, Luo JH, Wang W, Qiu S, Yang W, et al. 2003. Surface expression and co-localization of NMDA receptor and AMPA receptor on dendritic tree of hippocampal neurons in culture. Zhejiang Da Xue Xue Bao Yi Xue Ban 32: 470–474.
• Huettner JE. 2003. Kainate receptors and synaptic transmission. Prog Neurobiol 70: 387–407.
• Humphries C, Mortimer A, Hirsch S, de Belleroche J. 1996. NMDA receptor mRNA correlation with antemortem cognitive impairment in schizophrenia. Neuroreport 7: 2051–2055.
• Huntley GW, Morrison JH, Prikhozhan A, Sealfon SC. 1992. Localization of multiple dopamine receptor subtype mRNAs in human and monkey motor cortex and striatum. Brain Res Mol Brain Res 15: 181–188.
• Huntsman MM, Tran BV, Potkin SG, Bunney WE Jr, Jones EG. 1998. Altered ratios of alternatively spliced long and short gamma2 subunit mRNAs of the gamma-amino butyrate type A receptor in prefrontal cortex of schizophrenics. Proc Natl Acad Sci USA 95: 15066–15071.
• Hurst RS, Hajos M, Raggenbass M, Wall TM, Higdon NR, et al. 2005. A novel positive allosteric modulator of the alpha7 neuronal nicotinic acetylcholine receptor: In vitro and in vivo characterization. J Neurosci 25: 4396–4405.
• Ibrahim HM, Hogg AJ Jr, Healy DJ, Haroutunian V, Davis KL, et al. 2000. Ionotropic glutamate receptor binding and subunit mRNA expression in thalamic nuclei in schizophrenia. Am J Psychiatry 157: 1811–1823.
• Imai C, Sugai T, Iritani S, Niizato K, Nakamura R, Makifuchi T, Kakita A, Takahashi H, Nawa H. 2001. A quantitative study on the expression of synapsin II and N-ethylmaleimide-sensitive fusion protein in schizophrenic patients. Neurosci Lett 305(3): 185–188.
• Impagnatiello F, Guidotti AR, Pesold C, Dwivedi Y, Caruncho H, et al. 1998. A decrease of reelin expression as a putative vulnerability factor in schizophrenia. Proc Natl Acad Sci USA 95: 15718–15723.
• Irving AJ, Coutts AA, Harvey J, Rae MG, Mackie K, et al. 2000. Functional expression of cell surface cannabinoid CB(1) receptors on presynaptic inhibitory terminals in cultured rat hippocampal neurons. Neuroscience 98: 253–262.
• Ishikawa M, Mizukami K, Iwakiri M, Hidaka S, Asada T. 2004a. GABAA receptor gamma subunits in the prefrontal cortex of patients with schizophrenia and bipolar disorder. Neuroreport 15: 1809–1812.
• Ishikawa M, Mizukami K, Iwakiri M, Hidaka S, Asada T. 2004b. Immunohistochemical and immunoblot study of GABA(A) alpha1 and beta2/3 subunits in the prefrontal cortex of subjects with schizophrenia and bipolar disorder. Neurosci Res 50: 77–84.
• Iwabuchi K, Ito C, Tashiro M, Kato M, Kano M, et al. 2005. Histamine H1 receptors in schizophrenic patients measured by positron emission tomography. Eur Neuropsychopharmacol 15: 185–191.
• Iwamoto K, Kato T. 2003. RNA editing of serotonin 2C receptor in human postmortem brains of major mental disorders. Neurosci Lett 346(3): 169–172.
• Jaber M, Robinson SW, Missale C, Caron MG. 1996. Dopamine receptors and brain function. Neuropharmacology 35: 1503–1519.
• Jaekel B, Muhlberg K, Garcia de Arriba S, Reichenbach A, Verdaguer E, et al. 2006. Neuroprotection associated with alternative splicing of NMDA receptors in rat cortical neurons. Br J Pharmacol 147: 622–633.
• Jansen KL, Dragunow M, Faull RL, Leslie RA. 1991. Autoradiographic visualisation of [3H]DTG binding to sigma receptors, [3H]TCP binding sites, and L-[3H]glutamate binding to NMDA receptors in human cerebellum. Neurosci Lett 125: 143–146.
• Jarai Z, Wagner JA, Varga K, Lake KD, Compton DR, et al. 1999. Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proc Natl Acad Sci USA 96: 14136–14141.
• Jones BE. 1993. The organization of central cholinergic systems and their functional importance in sleep-waking states. Prog Brain Res 98: 61–71.
• Joyce JN, Goldsmith SG, Gurevich EV. 1997. Limbic circuits and monoamine receptors: Dissecting the effects of antipsychotics from disease processes. J Psychiatr Res 31: 197–217.
• Joyce JN, Lexow N, Kim SJ, Artymyshyn R, Senzon S, et al. 1992. Distribution of beta-adrenergic receptor subtypes in human post-mortem brain: Alterations in limbic regions of schizophrenics. Synapse 10: 228–246.
• Joyce JN, Meador-Woodruff JH. 1997. Linking the family of D2 receptors to neuronal circuits in human brain: Insights into schizophrenia. Neuropsychopharmacology 16: 375–384.
• Joyce JN, Shane A, Lexow N, Winokur A, Casanova MF, et al. 1993. Serotonin uptake sites and serotonin receptors are altered in the limbic system of schizophrenics. Neuropsychopharmacology 8: 315–336.
• Jun JY, Choi S, Yeum CH, Chang IY, You HJ, et al. 2004. Substance P induces inward current and regulates pacemaker currents through tachykinin NK1 receptor in cultured interstitial cells of Cajal of murine small intestine. Eur J Pharmacol 495: 35–42.
• Kamali F. 2001. Osanetant Sanofi-Synthelabo. Curr Opin Investig Drugs 2: 950–956.
• Kasa P. 1986. The cholinergic systems in brain and spinal cord. Prog Neurobiol 26: 211–272.
• Kaupmann K, Huggel K, Heid J, Flor PJ, Bischoff S, et al. 1997. Expression cloning of GABA(B) receptors uncovers similarity to metabotropic glutamate receptors. Nature 386: 239–246.
• Kaupmann K, Malitschek B, Schuler V, Heid J, Froestl W, et al. 1998. GABA(B)-receptor subtypes assemble into functional heteromeric complexes. Nature 396: 683–687.
• Kerwin R, Patel S, Meldrum B. 1990. Quantitative autoradiographic analysis of glutamate binding sites in the hippocampal formation in normal and schizophrenic brain post mortem. Neuroscience 39: 25–32.
• Kew JN, Kemp JA. 2005. Ionotropic and metabotropic glutamate receptor structure and pharmacology. Psychopharmacology (Berl) 179: 4–29.
• Kharazia VN, Phend KD, Rustioni A, Weinberg RJ. 1996. EM colocalization of AMPA and NMDA receptor subunits at synapses in rat cerebral cortex. Neurosci Lett 210: 37–40.
• Klausberger T, Roberts JD, Somogyi P. 2002. Cell type- and input-specific differences in the number and subtypes of synaptic GABA(A) receptors in the hippocampus. J Neurosci 22: 2513–2521.
• Klimek V, Rajkowska G, Luker SN, Dilley G, Meltzer HY, et al. 1999. Brain noradrenergic receptors in major depression and schizophrenia. Neuropsychopharmacology 21: 69–81.
• Knable MB, Hyde TM, Herman MM, Carter JM, Bigelow L, et al. 1994. Quantitative autoradiography of dopamine-D1 receptors, D2 receptors, and dopamine uptake sites in postmortem striatal specimens from schizophrenic patients. Biol Psychiatry 36: 827–835.
• Knable MB, Hyde TM, Murray AM, Herman MM, Kleinman JE. 1996. A postmortem study of frontal cortical dopamine D1 receptors in schizophrenics, psychiatric controls, and normal controls. Biol Psychiatry 40: 1191–1199.
• Koethe D, Llenos IC, Dulay JR, Hoyer C, Torrey EF, et al. 2007. Expression of CB(1) cannabinoid receptor in the anterior cingulate cortex in schizophrenia, bipolar disorder, and major depression. J Neural Transm : 114: 1055–1063.
• Koh PO, Undie AS, Kabbani N, Levenson R, Goldman-Rakic PS, et al. 2003. Up-regulation of neuronal calcium sensor-1 (NCS-1) in the prefrontal cortex of schizophrenic and bipolar patients. Proc Natl Acad Sci USA 100: 313–317.
• Kornhuber J, Mack-Burkhardt F, Riederer P, Hebenstreit GF, Reynolds GP, et al. 1989. [3H]MK-801 binding sites in postmortem brain regions of schizophrenic patients. J Neural Transm 77: 231–236.
• Kratskin I, Kenigfest N, Rio JP, Djediat C, Reperant J. 2006. Immunocytochemical localization of the GABAB2 receptor subunit in the glomeruli of the mouse main olfactory bulb. Neurosci Lett 402: 121–125.
• Kraus JE, Nadler JV, McNamara JO. 1996. Regulation of alternative splicing of NMDAR1 in the kindling model. Brain Res Mol Brain Res 41: 97–104.
• Krieger P, Hellgren-Kotaleski J, Kettunen P, El Manira AJ. 2000. Interaction between metabotropic and ionotropic glutamate receptors regulates neuronal network activity. J Neurosci 20: 5382–5391.
• Kristiansen LV, Beneyto M, Haroutunian V, Meador-Woodruff JH. 2006. Changes in NMDA receptor subunits and interacting PSD proteins in dorsolateral prefrontal and anterior cingulate cortex indicate abnormal regional expression in schizophrenia. Mol Psychiatry 11(8): 737–747.
• Kristiansen LV, Huerta I, Beneyto M, Meador-Woodruff JH. 2007. NMDA receptors and schizophrenia. Curr Opin Pharmacol 7: 48–55.
• Kuner R, Kohr G, Grunewald S, Eisenhardt G, Bach A, et al. 1999. Role of heteromer formation in GABAB receptor function. Science 283: 74–77.
• Kurumaji A, Ishimaru M, Toru M. 1992. Alpha-[3H]amino-3-hydroxy-5-methylisoxazole-4-propionic acid binding to human cerebral cortical membranes: Minimal changes in postmortem brains of chronic schizophrenics. J Neurochem 59: 829–837.
• Lahti AC, Weiler MA, Tamara Michaelidis BA, Parwani A, Tamminga CA. 2001. Effects of ketamine in normal and schizophrenic volunteers. Neuropsychopharmacology 25: 455–467.
• Lahti RA, Roberts RC, Conley RR, Cochrane EV, Mutin A, et al. 1996. D2-type dopamine receptors in postmortem human brain sections from normal and schizophrenic subjects. Neuroreport 7: 1945–1948.
• Lambe EK, Picciotto MR, Aghajanian GK. 2003. Nicotine induces glutamate release from thalamocortical terminals in prefrontal cortex. Neuropsychopharmacology 28: 216–225.
• Lan CT, Shieh JY, Wen CY, Tan CK, Ling EA. 1996. Ultrastructural localization of acetylcholinesterase and choline acetyltransferase in oligodendrocytes, glioblasts and vascular endothelial cells in the external cuneate nucleus of the gerbil. Anat Embryol (Berl) 194: 177–185.
• Lapish CC, Kroener S, Durstewitz D, Lavin A, Seamans JK. 2007. The ability of the mesocortical dopamine system to operate in distinct temporal modes. Psychopharmacology (Berl) 191: 609–625.
• Largent BL, Gundlach AL, Snyder SH. 1986. Pharmacological and autoradiographic discrimination of sigma and phencyclidine receptor binding sites in brain with (+)-[3H]SKF 10,047, (+)-[3H]-3-[3-hydroxyphenyl]-N-(1-propyl)piperidine and [3H]-1-[1-(2-thienyl)cyclohexyl]piperidine. J Pharmacol Exp Ther 238: 739–748.
• Laruelle M, Abi-Dargham A, Casanova MF, Toti R, Weinberger DR, Kleinman JE. 1993. Selective abnormalities of prefrontal serotonergic receptors in schizophrenia. A postmortem study. Arch Gen Psychiatry 50(10): 810–818.
• Law AJ, Deakin JF. 2001. Asymmetrical reductions of hippocampal NMDAR1 glutamate receptor mRNA in the psychoses. Neuroreport 12: 2971–2974.
• Le Corre S, Harper CG, Lopez P, Ward P, Catts S. 2000. Increased levels of expression of an NMDARI splice variant in the superior temporal gyrus in schizophrenia. Neuroreport 11: 983–986.
• Le Moine C, Gaspar P. 1998. Subpopulations of cortical GABAergic interneurons differ by their expression of D1 and D2 dopamine receptor subtypes. Brain Res Mol Brain Res 58: 231–236.
• Lee SH, Simonetta A, Sheng M. 2004. Subunit rules governing the sorting of internalized AMPA receptors in hippocampal neurons. Neuron 43: 221–236.
• Leonard S, Gault J, Adams C, Breese CR, Rollins Y, et al. 1998. Nicotinic receptors, smoking and schizophrenia. Restor Neurol Neurosci 12: 195–201.
• Levey AI, Kitt CA, Simonds WF, Price DL, Brann MR. 1991. Identification and localization of muscarinic acetylcholine receptor proteins in brain with subtype-specific antibodies. J Neurosci 11: 3218–3226.
• Levin ED, Bradley A, Addy N, Sigurani N. 2002. Hippocampal alpha 7 and alpha 4 beta 2 nicotinic receptors and working memory. Neuroscience 109: 757–765.
• Lewis DA, Cruz D, Eggan S, Erickson S. 2004. Postnatal development of prefrontal inhibitory circuits and the pathophysiology of cognitive dysfunction in schizophrenia. Ann NY Acad Sci 1021: 64–76.
• Lewis DA, Hashimoto T, Volk DW. 2005. Cortical inhibitory neurons and schizophrenia. Nat Rev Neurosci 6: 312–324.
• Lewis DA, Pierri JN, Volk DW, Melchitzky DS, Woo TU. 1999. Altered GABA neurotransmission and prefrontal cortical dysfunction in schizophrenia. Biol Psychiatry 46: 616–626.
• Lipska BK, Mitkus S, Caruso M, Hyde TM, Chen J, Vakkalanka R, Straub RE, Weinberger DR, Kleinman JE. 2006. RGS4 mRNA expression in postmortem human cortex is associated with COMT Val158Met genotype and COMT enzyme activity. Hum Mol Genet 15(18): 2804–2812.
• Loftis JM, Janowsky A. 2003. The N-methyl-D-aspartate receptor subunit NR2B: Localization, functional properties, regulation, and clinical implications. Pharmacol Ther 97: 55–85.
• Lopez-Figueroa AL, Norton CS, Lopez-Figueroa MO, Armellini-Dodel D, Burke S, et al. 2004. Serotonin 5-HT1A, 5-HT1B, and 5-HT2A receptor mRNA expression in subjects with major depression, bipolar disorder, and schizophrenia. Biol Psychiatry 55: 225–233.
• Lord JA, Waterfield AA, Hughes J, Kosterlitz HW. 1977. Endogenous opioid peptides: Multiple agonists and receptors. Nature 267: 495–499.
• Lu W, Ziff EB. 2005. PICK1 interacts with ABP/GRIP to regulate AMPA receptor trafficking. Neuron 47: 407–421.
• Luo JH, Fu ZY, Losi G, Kim BG, Prybylowski K, et al. 2002. Functional expression of distinct NMDA channel subunits tagged with green fluorescent protein in hippocampal neurons in culture. Neuropharmacology 42: 306–318.
• Lynn AB, Herkenham M. 1994. Localization of cannabinoid receptors and nonsaturable high-density cannabinoid binding sites in peripheral tissues of the rat: Implications for receptor-mediated immune modulation by cannabinoids. J Pharmacol Exp Ther 268: 1612–1623.
• Mackay AV, Iversen LL, Rossor M, Spokes E, Bird E, et al. 1982. Increased brain dopamine and dopamine receptors in schizophrenia. Arch Gen Psychiatry 39: 991–997.
• Mackie K, Lai Y, Westenbroek R, Mitchell R. 1995. Cannabinoids activate an inwardly rectifying potassium conductance and inhibit Q-type calcium currents in AtT20 cells transfected with rat brain cannabinoid receptor. J Neurosci 15: 6552–6561.
• Maejima T, Hashimoto K, Yoshida T, Aiba A, Kano M. 2001. Presynaptic inhibition caused by retrograde signal from metabotropic glutamate to cannabinoid receptors. Neuron 31: 463–475.
• Maggi CA, Giuliani S, Santicioli P, Regoli D, Meli A. 1987. Peripheral effects of neurokinins: Functional evidence for the existence of multiple receptors. J Auton Pharmacol 7: 11–32.
• Maggi CA, Patacchini R, Rovero P, Giachetti A. 1993. Tachykinin receptors and tachykinin receptor antagonists. J Auton Pharmacol 13: 23–93.
• Malenka RC, Bear MF. 2004. LTP and LTD: An embarrassment of riches. Neuron 44: 5–21.
• Mancama D, Arranz MJ, Landau S, Kerwin R. 2003. Reduced expression of the muscarinic 1 receptor cortical subtype in schizophrenia. Am J Med Genet B Neuropsychiatr Genet 119: 2–6.
• Mannaioni G, Marino MJ, Valenti O, Traynelis SF, Conn PJ. 2001. Metabotropic glutamate receptors 1 and 5 differentially regulate CA1 pyramidal cell function. J Neurosci 21: 5925–5934.
• Mao L, Wang JQ. 2002. Interactions between ionotropic and metabotropic glutamate receptors regulate cAMP response element-binding protein phosphorylation in cultured striatal neurons. Neuroscience 115: 395–402.
• Martin IL, Dunn MJ. 2002. GABA receptors. Tocris Rev 20: 1–8.
• Martin LF, Freedman R. 2007. Schizophrenia and the alpha7 Nicotinic Acetylcholine Receptor. Int Rev Neurobiol 78: 225–246.
• Martin WR, Eades CG, Thompson JA, Huppler RE, Gilbert PE. 1976. The effects of morphine- and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog. J Pharmacol Exp Ther 197: 517–532.
• Martin-Ruiz CM, Haroutunian VH, Long P, Young AH, Davis KL, et al. 2003. Dementia rating and nicotinic receptor expression in the prefrontal cortex in schizophrenia. Biol Psychiatry 54: 1222–1233.
• Maruo J, Yoshida A, Shimohira I, Matsuno K, Mita S, et al. 2000. Binding of [35S]GTPgammaS stimulated by (+)-pentazocine sigma receptor agonist, is abundant in the guinea pig spleen. Life Sci 67: 599–603.
• Marutle A, Zhang X, Court J, Piggott M, Johnson M, et al. 2001. Laminar distribution of nicotinic receptor subtypes in cortical regions in schizophrenia. J Chem Neuroanat 22: 115–126.
• Masu M, Nakajima Y, Moriyoshi K, Ishii T, Akazawa C, et al. 1993. Molecular characterization of NMDA and metabotropic glutamate receptors. Ann NY Acad Sci 707: 153–164.
• Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. 1990. Structure of a cannabinoid receptor and fqnctional expression of the cloned cDNA. Nature 346: 561–564.
• Matsumoto I, Inoue Y, Iwazaki T, Pavey G, Dean B. 2005. 5-HT2A and muscarinic receptors in schizophrenia: A postmortem study. Neurosci Lett 379: 164–168.
• Mayer ML. 2005. Glutamate receptor ion channels. Curr Opin Neurobiol 15: 282–288.
• McCormick DA, Prince DA. 1985. Two types of muscarinic response to acetylcholine in mammalian cortical neurons. Proc Natl Acad Sci USA 82: 6344–6348.
• McCullumsmith RE, Kristiansen LV, Beneyto M, Scarr E, Dean B, et al. 2007. Decreased NR1, NR2A, and SAP102 transcript expression in the hippocampus in bipolar disorder. Brain Res 1127: 108–118.
• McGehee DS. 2002. Nicotinic receptors and hippocampal synaptic plasticity… it’s all in the timing. Trends Neurosci 25: 171–172.
• McKernan RM, Whiting PJ. 1996. Which GABAA-receptor subtypes really occur in the brain? Trends Neurosci 19: 139–143.
• McKinney M. 1993. Muscarinic receptor subtype-specific coupling to second messengers in neuronal systems. Prog Brain Res 98: 333–340.
• McVey M, Ramsay D, Kellett E, Rees S, Wilson S, et al. 2001. Monitoring receptor oligomerization using time-resolved fluorescence resonance energy transfer and bioluminescence resonance energy transfer. The human delta-opioid receptor displays constitutive oligomerization at the cell surface, which is not regulated by receptor occupancy. J Biol Chem 276: 14092–14099.
• Meador-Woodruff JH, Damask SP, Wang J, Haroutunian V, Davis KL, et al. 1996. Dopamine receptor mRNA expression in human striatum and neocortex. Neuropsychopharmacology 15: 17–29.
• Meador-Woodruff JH, Davis KL, Haroutunian V. 2001. Abnormal kainate receptor expression in prefrontal cortex in schizophrenia. Neuropsychopharmacology 24: 545–552.
• Meador-Woodruff JH, Grandy DK, Van Tol HH, Damask SP, Little KY, et al. 1994. Dopamine receptor gene expression in the human medial temporal lobe. Neuropsychopharmacology 10: 239–248.
• Meador-Woodruff JH, Haroutunian V, Powchik P, Davidson M, Davis KL, et al. 1997. Dopamine receptor transcript expression in striatum and prefrontal and occipital cortex. Focal abnormalities in orbitofrontal cortex in schizophrenia. Arch Gen Psychiatry 54: 1089–1095.
• Meador-Woodruff JH, Healy DJ. 2000. Glutamate receptor expression in schizophrenic brain. Brain Res Brain Res Rev 31: 288–294.
• Meador-Woodruff JH, Mansour A, Grandy DK, Damask SP, Civelli O, et al. 1992. Distribution of D5 dopamine receptor mRNA in rat brain. Neurosci Lett 145: 209–212.
• Mellor JR. 2006. Synaptic plasticity of kainate receptors. Biochem Soc Trans 34: 949–951.
• Meltzer HY, Arvanitis L, Bauer D, Rein W. 2004. Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder. Am J Psychiatry 161: 975–984.
• Meltzer HY, Li Z, Kaneda Y, Ichikawa J. 2003. Serotonin receptors: Their key role in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 27: 1159–1172.
• Mesulam MM. 1990. Human brain cholinergic pathways. Prog Brain Res 84: 231–241.
• Mi R, Sia GM, Rosen K, Tang X, Moghekar A, et al. 2004. AMPA receptor-dependent clustering of synaptic NMDA receptors is mediated by Stargazin and NR2A/B in spinal neurons and hippocampal interneurons. Neuron 44: 335–349.
• Michaelis EK. 1998. Molecular biology of glutamate receptors in the central nervous system and their role in excitotoxicity, oxidative stress and aging. Prog Neurobiol 54: 369–415.
• Michels G, Moss SJ. 2007. GABAA receptors: Properties and trafficking. Crit Rev Biochem Mol Biol 42: 3–14.
• Mirnics K, Middleton FA, Marquez A, Lewis DA, Levitt P. 2000. Molecular characterization of schizophrenia viewed by microarray analysis of gene expression in prefrontal cortex. Neuron 28(1): 53–67.
• Mirnics K, Middleton FA, Stanwood GD, Lewis DA, Levitt P. 2001. Disease-specific changes in regulator of G-protein signaling 4 (RGS4) expression in schizophrenia. Mol Psychiatry 6: 293–301.
• Mirza NR, Peters D, Sparks RG. 2003. Xanomeline and the antipsychotic potential of muscarinic receptor subtype selective agonists. CNS Drug Rev 9: 159–186.
• Missale C, Nash SR, Robinson SW, Jaber M, Caron MG. 1998. Dopamine receptors: From structure to function. Physiol Rev 78: 189–225.
• Mita T, Hanada S, Nishino N, Kuno T, Nakai H, Yamadori T, Mizoi Y, Tanaka C. 1986. Decreased serotonin S2 and increased dopamine D2 receptors in chronic schizophrenics. Biol Psychiatry 21(14): 1407–1414.
• Mizukami K, Ishikawa M, Hidaka S, Iwakiri M, Sasaki M, et al. 2002. Immunohistochemical localization of GABAB receptor in the entorhinal cortex and inferior temporal cortex of schizophrenic brain. Prog Neuropsychopharmacol Biol Psychiatry 26: 393–396.
• Mizukami K, Sasaki M, Ishikawa M, Iwakiri M, Hidaka S, et al. 2000. Immunohistochemical localization of gamma-aminobutyric acid(B) receptor in the hippocampus of subjects with schizophrenia. Neurosci Lett 283: 101–104.
• Moghaddam B. 2004. Targeting metabotropic glutamate receptors for treatment of the cognitive symptoms of schizophrenia. Psychopharmacology (Berl) 174: 39–44.
• Mohler H. 2006. GABA(A) receptor diversity and pharmacology. Cell Tissue Res 326: 505–516.
• Mohler H, Fritschy JM, Crestani F, Hensch T, Rudolph U. 2004. Specific GABA(A) circuits in brain development and therapy. Biochem Pharmacol 68: 1685–1690.
• Monyer H, Sprengel R, Schoepfer R, Herb A, Higuchi M, et al. 1992. Heteromeric NMDA receptors: Molecular and functional distinction of subtypes. Science 256: 1217–1221.
• Mu Y, Otsuka T, Horton AC, Scott DB, Ehlers MD. 2003. Activity-dependent mRNA splicing controls ER export and synaptic delivery of NMDA receptors. Neuron 40: 581–594.
• Mulcrone J, Kerwin RW. 1996. No difference in the expression of the D4 gene in post-mortem frontal cortex from controls and schizophrenics. Neurosci Lett 219: 163–166.
• Munro S, Thomas KL, Abu-Shaar M. 1993. Molecular characterization of a peripheral receptor for cannabinoids. Nature 365: 61–65.
• Murray AM, Hyde TM, Knable MB, Herman MM, Bigelow LB, et al. 1995. Distribution of putative D4 dopamine receptors in postmortem striatum from patients with schizophrenia. J Neurosci 15: 2186–2191.
• Nakai T, Kitamura N, Hashimoto T, Kajimoto Y, Nishino N, et al. 1991. Decreased histamine H1 receptors in the frontal cortex of brains from patients with chronic schizophrenia. Biol Psychiatry 30: 349–356.
• Nashmi R, Lester HA. 2006. CNS localization of neuronal nicotinic receptors. J Mol Neurosci 30: 181–184.
• Neve KA, Seamans JK, Trantham-Davidson H. 2004. Dopamine receptor signaling. J Recept Signal Transduct Res 24: 165–205.
• Newell KA, Deng C, Huang XF. 2006. Increased cannabinoid receptor density in the posterior cingulate cortex in schizophrenia. Exp Brain Res 172: 556–560.
• Newell KA, Zavitsanou K, Huang XF. 2005. Ionotropic glutamate receptor binding in the posterior cingulate cortex in schizophrenia patients. Neuroreport 16: 1363–1367.
• Newell KA, Zavitsanou K, Jew SK, Huang XF. 2007. Alterations of muscarinic and GABA receptor binding in the posterior cingulate cortex in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 31: 225–233.
• Ni Q, Xu H, Partilla JS, de Costa BR, Rice KC, et al. 1995. Opioid peptide receptor studies. 3. Interaction of opioid peptides and other drugs with four subtypes of the kappa 2 receptor in guinea pig brain. Peptides 16: 1083–1095.
• Noga JT, Hyde TM, Bachus SE, Herman MM, Kleinman JE. 2001. AMPA receptor binding in the dorsolateral prefrontal cortex of schizophrenics and controls. Schizophr Res 48: 361–363.
• Noga JT, Wang H. 2002. Further postmortem autoradiographic studies of AMPA receptor binding in schizophrenia. Synapse 45: 250–258.
• Nudmamud-Thanoi S, Reynolds GP. 2004. The NR1 subunit of the glutamate/NMDA receptor in the superior temporal cortex in schizophrenia and affective disorders. Neurosci Lett 372: 173–177.
• Ohnuma T, Augood SJ, Arai H, McKenna PJ, Emson PC. 1998. Expression of the human excitatory amino acid transporter 2 and metabotropic glutamate receptors 3 and 5 in the prefrontal cortex from normal individuals and patients with schizophrenia. Brain Res Mol Brain Res 56: 207–217.
• Ohnuma T, Augood SJ, Arai H, McKenna PJ, Emson PC. 1999. Measurement of GABAergic parameters in the prefrontal cortex in schizophrenia: Focus on GABA content, GABA(A) receptor alpha-1 subunit messenger RNA and human GABA transporter-1 (HGAT-1) messenger RNA expression. Neuroscience 93: 441–448.
• Ohnuma T, Kato H, Arai H, Faull RL, McKenna PJ, et al. 2000a. Gene expression of PSD95 in prefrontal cortex and hippocampus in schizophrenia. Neuroreport 11: 3133–3137.
• Ohnuma T, Tessler S, Arai H, Faull RL, McKenna PJ, et al. 2000b. Gene expression of metabotropic glutamate receptor 5 and excitatory amino acid transporter 2 in the schizophrenic hippocampus. Brain Res Mol Brain Res 85: 24–31.
• Onaivi ES, Ishiguro H, Gong JP, Patel S, Perchuk A, et al. 2006. Discovery of the presence and functional expression of cannabinoid CB2 receptors in brain. Ann NY Acad Sci 1074: 514–536.
• Owen F, Bourne RC, Poulter M, Crow TJ, Paterson SJ, et al. 1985. Tritiated etorphine and naloxone binding to opioid receptors in caudate nucleus in schizophrenia. Br J Psychiatry 146: 507–509.
• Owen F, Cross AJ, Crow TJ, Longden A, Poulter M, et al. 1978. Increased dopamine-receptor sensitivity in schizophrenia. Lancet 2: 223–226.
• Page NM. 2004. Hemokinins and endokinins. Cell Mol Life Sci 61: 1652–1663.
• Pantazopoulos H, Stone D, Walsh J, Benes FM. 2004. Differences in the cellular distribution of D1 receptor mRNA in the hippocampus of bipolars and schizophrenics. Synapse 54: 147–155.
• Park M, Penick EC, Edwards JG, Kauer JA, Ehlers MD. 2004. Recycling endosomes supply AMPA receptors for LTP. Science 305: 1972–1975.
• Pasternak GW, Wood PJ. 1986. Multiple mu opiate receptors. Life Sci 38: 1889–1898.
• Payne GW, Neuman RS. 1997. Effects of hypomagnesia on histamine H1 receptor-mediated facilitation of NMDA responses. Br J Pharmacol 121: 199–204.
• Paz RD, Andreasen NC, Daoud SZ, Conley R, Roberts R, et al. 2006. Increased expression of activity-dependent genes in cerebellar glutamatergic neurons of patients with schizophrenia. Am J Psychiatry 163: 1829–1831.
• Peckys D, Hurd YL. 2001. Prodynorphin and kappa opioid receptor mRNA expression in the cingulate and prefrontal cortices of subjects diagnosed with schizophrenia or affective disorders. Brain Res Bull 55: 619–624.
• Pellicciari R, Costantino G, Marinozzi M, Macchiarulo A, Camaioni E, et al. 2001. Metabotropic glutamate receptors: Structure and new subtype-selective ligands. Farmaco 56: 91–94.
• Perez-Garci E, Gassmann M, Bettler B, Larkum ME. 2006. The GABAB1b isoform mediates long-lasting inhibition of dendritic Ca2+ spikes in layer 5 somatosensory pyramidal neurons. Neuron 50: 603–616.
• Pierri JN, Chaudry AS, Woo TU, Lewis DA. 1999. Alterations in chandelier neuron axon terminals in the prefrontal cortex of schizophrenic subjects. Am J Psychiatry 156: 1709–1719.
• Pin JP, Galvez T, Prezeau L. 2003. Evolution, structure, and activation mechanism of family 3/C G-protein-coupled receptors. Pharmacol Ther 98: 325–354.
• Pisani A, Gubellini P, Bonsi P, Conquet F, Picconi B, et al. 2001. Metabotropic glutamate receptor 5 mediates the potentiation of N-methyl-D-aspartate responses in medium spiny striatal neurons. Neuroscience 106: 579–587.
• Polesskaya OO, Sokolov BP. 2002. Differential expression of the “C” and “T” alleles of the 5-HT2A receptor gene in the temporal cortex of normal individuals and schizophrenics. J Neurosci Res 67: 812–822.
• Popken GJ, Leggio MG, Bunney WE, Jones EG. 2002. Expression of mRNAs related to the GABAergic and glutamatergic neurotransmitter systems in the human thalamus: Normal and schizophrenic. Thalamus Relat Syst 1: 349–369.
• Porter RH, Eastwood SL, Harrison PJ. 1997. Distribution of kainate receptor subunit mRNAs in human hippocampus, neocortex and cerebellum, and bilateral reduction of hippocampal GluR6 and KA2 transcripts in schizophrenia. Brain Res 751: 217–231.
• Pralong D, Tomaskovic-Crook E, Opeskin K, Copolov D, Dean B. 2000. Serotonin(2A) receptors are reduced in the planum temporale from subjects with schizophrenia. Schizophr Res 44(1): 35–45.
• Prather PL, Martin NA, Breivogel CS, Childers SR. 2000. Activation of cannabinoid receptors in rat brain by WIN 55212–2 produces coupling to multiple G protein alpha-subunits with different potencies. Mol Pharmacol 57: 1000–1010.
• Prell GD, Green JP, Kaufmann CA, Khandelwal JK, Morrishow AM, et al. 1995. Histamine metabolites in cerebrospinal fluid of patients with chronic schizophrenia: Their relationships to levels of other aminergic transmitters and ratings of symptoms. Schizophr Res 14: 93–104.
• Premont RT, Hall RA. 2002. Identification of novel G protein-coupled receptor-interacting proteins. Methods Enzymol 343: 611–621.
• Quik M, Polonskaya Y, Gillespie A, Jakowec M, Lloyd GK, et al. 2000. Localization of nicotinic receptor subunit mRNAs in monkey brain by in situ hybridization. J Comp Neurol 425: 58–69.
• Quirion R, Bowen WD, Itzhak Y, Junien JL, Musacchio JM, et al. 1992. A proposal for the classification of sigma binding sites. Trends Pharmacol Sci 13: 85–86.
• Raedler TJ, Bymaster FP, Tandon R, Copolov D, Dean B. 2007. Towards a muscarinic hypothesis of schizophrenia. Mol Psychiatry 12: 232–246.
• Raymond JR. 1995. Multiple mechanisms of receptor-G protein signaling specificity. Am J Physiol 269: F141–F158.
• Reynolds GP, Rossor MN, Iversen LL. 1983. Preliminary studies of human cortical 5-HT2 receptors and their involvement in schizophrenia and neuroleptic drug action. J Neural Transm Suppl.; 18: 273–277.
• Reynolds GP, Mason SL. 1994. Are striatal dopamine D4 receptors increased in schizophrenia? J Neurochem 63: 1576–1577.
• Reynolds GP, Zhang ZJ, Beasley CL. 2001. Neurochemical correlates of cortical GABAergic deficits in schizophrenia: Selective losses of calcium binding protein immunoreactivity. Brain Res Bull 55: 579–584.
• Richardson-Burns SM, Haroutunian V, Davis KL, Watson SJ, Meador-Woodruff JH. 2000. Metabotropic glutamate receptor mRNA expression in the schizophrenic thalamus. Biol Psychiatry 47: 22–28.
• Riedel G, Davies SN. 2005. Cannabinoid function in learning, memory and plasticity. Handb Exp Pharmacol 445–477.
• Rioux L, Nissanov J, Joyce JN. 1998. Increased number of [I-125] BH-substance P receptors in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 22: 1295–1299.
• Roberts DA, Balderson D, Pickering-Brown SM, Deakin JF, Owen F. 1994. The abundance of mRNA for dopamine D2 receptor isoforms in brain tissue from controls and schizophrenics. Brain Res Mol Brain Res 25: 173–175.
• Roberts DA, Balderson D, Pickering-Brown SM, Deakin JF, Owen F. 1996. The relative abundance of dopamine D4 receptor mRNA in post mortem brains of schizophrenics and controls. Schizophr Res 20: 171–174.
• Roberts GW, Ferrier IN, Lee Y, Crow TJ, Johnstone EC, et al. 1983. Peptides, the limbic lobe and schizophrenia. Brain Res 288: 199–211.
• Rodriguez-Moreno A. 2006. The role of kainate receptors in the regulation of excitatory synaptic transmission in the hippocampus. Rev Neurol 42: 282–287.
• Romanelli MN, Gratteri P, Guandalini L, Martini E, Bonaccini C, et al. 2007. Central nicotinic receptors: Structure, function, ligands, and therapeutic potential. ChemMedChem 2: 746–767.
• Romero G, Perez MP, Carceller A, Monroy X, Farre AJ, et al. 2000. Changes in phosphoinositide signalling activity and levels of the alpha subunit of G(q/11) protein in rat brain induced by E-5842, a sigma(1) receptor ligand and potential atypical antipsychotic. Neurosci Lett 290: 189–192.
• Ronesi J, Gerdeman GL, Lovinger DM. 2004. Disruption of endocannabinoid release and striatal long-term depression by postsynaptic blockade of endocannabinoid membrane transport. J Neurosci 24: 1673–1679.
• Roth BL, Hanizavareh SM, Blum AE. 2004. Serotonin receptors represent highly favorable molecular targets for cognitive enhancement in schizophrenia and other disorders. Psychopharmacology (Berl) 174: 17–24.
• Rothman RB, Bykov V, de Costa BR, Jacobson AE, Rice KC, et al. 1990. Evidence for four opioid kappa binding sites in guinea pig brain. Prog Clin Biol Res 328: 9–12.
• Rouse ST, Levey AI. 1997. Muscarinic acetylcholine receptor immunoreactivity after hippocampal commissural/associational pathway lesions: Evidence for multiple presynaptic receptor subtypes. J Comp Neurol 380: 382–394.
• Royston MC, Slater P, Simpson MD, Deakin JF. 1991. Analysis of laminar distribution of kappa opiate receptor in human cortex: Comparison between schizophrenia and normal. J Neurosci Methods 36: 145–153.
• Rudolph U, Crestani F, Benke D, Brunig I, Benson JA, et al. 1999. Benzodiazepine actions mediated by specific gamma-aminobutyric acid(A) receptor subtypes. Nature 401: 796–800.
• Ruiz A, Sachidhanandam S, Utvik JK, Coussen F, Mulle C. 2005. Distinct subunits in heteromeric kainate receptors mediate ionotropic and metabotropic function at hippocampal mossy fiber synapses. J Neurosci 25: 11710–11718.
• Ruiz J, Gabilondo AM, Meana JJ, Garcia-Sevilla JA. 1992. Increased [3H] raclopride binding sites in postmortem brains from schizophrenic violent suicide victims. Psychopharmacology (Berl) 109: 410–414.
• Rumbaugh G, Sia GM, Garner CC, Huganir RL. 2003. Synapse-associated protein-97 isoform-specific regulation of surface AMPA receptors and synaptic function in cultured neurons. J Neurosci 23: 4567–4576.
• Ryberg E, Vu HK, Larsson N, Groblewski T, Hjorth S, et al. 2005. Identification and characterisation of a novel splice variant of the human CB1 receptor. FEBS Lett 579: 259–264.
• Samovilova NN, Iarygin KN, Vinogradov VA. 1985. Specific binding of N-allylnormetazocine (SKF 10047), a ligand of sigma-opioid receptors, with liver membranes. Bioorg Khim 11: 1380–1384.
• Sanchez C, Rueda D, Segui B, Galve-Roperh I, Levade T, et al. 2001. The CB(1) cannabinoid receptor of astrocytes is coupled to sphingomyelin hydrolysis through the adaptor protein fan. Mol Pharmacol 59: 955–959.
• Santana N, Bortolozzi A, Serrats J, Mengod G, Artigas F. 2004. Expression of serotonin1A and serotonin2A receptors in pyramidal and GABAergic neurons of the rat prefrontal cortex. Cereb Cortex 14: 1100–1109.
• Saugstad JA, Marino MJ, Folk JA, Hepler JR, Conn PJ. 1998. RGS4 inhibits signaling by group I metabotropic glutamate receptors. J Neurosci 18: 905–913.
• Scarr E, Beneyto M, Meador-Woodruff JH, Deans B. 2005. Cortical glutamatergic markers in schizophrenia. Neuropsychopharmacology 30: 1521–1531.
• Scarr E, Keriakous D, Crossland N, Dean B. 2006. No change in cortical muscarinic M2, M3 receptors or [35S]GTPgammaS binding in schizophrenia. Life Sci 78: 1231–1237.
• Scarr E, Pavey G, Copolov D, Dean B. 2004. Hippocampal 5-hydroxytryptamine receptors: Abnormalities in postmortem brain from schizophrenic subjects. Schizophr Res 71: 383–392.
• Scarr E, Sundram S, Keriakous D, Dean B. 2007. Altered hippocampal muscarinic M4, but not M1, receptor expression from subjects with schizophrenia. Biol Psychiatry 61: 1161–1170.
• Schluter OM, Xu W, Malenka RC. 2006. Alternative N-terminal domains of PSD-95 and SAP97 govern activity-dependent regulation of synaptic AMPA receptor function. Neuron 51: 99–111.
• Schmauss C, Haroutunian V, Davis KL, Davidson M. 1993. Selective loss of dopamine D3-type receptor mRNA expression in parietal and motor cortices of patients with chronic schizophrenia. Proc Natl Acad Sci USA 90: 8942–8946.
• Scott DB, Blanpied TA, Ehlers MD. 2003. Coordinated PKA and PKC phosphorylation suppresses RXR-mediated ER retention and regulates the surface delivery of NMDA receptors. Neuropharmacology 45: 755–767.
• Scott DB, Blanpied TA, Swanson GT, Zhang C, Ehlers MD. 2001. An NMDA receptor ER retention signal regulated by phosphorylation and alternative splicing. J Neurosci 21: 3063–3072.
• Seamans JK, Yang CR. 2004. The principal features and mechanisms of dopamine modulation in the prefrontal cortex. Prog Neurobiol 74: 1–58.
• Seeman P. 1987. Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse 1: 133–152.
• Seeman P, Bzowej NH, Guan HC, Bergeron C, Reynolds GP, et al. 1987. Human brain D1 and D2 dopaeine receptors in schizophrenia, Alzheimer’s, Parkinson’s, and Huntington’s diseases. Neuropsychopharmacology 1: 5–15.
• Seeman P, Guan HC, Van Tol HH. 1993. Dopamine D4 receptors elevated in schizophrenia. Nature 365: 441–445.
• Seeman P, Ko F, Jack E, Greenstein R, Dean B. 2007. Consistent with dopamine supersensitivity, RGS9 expression is diminished in the amphetamine-treated animal model of schizophrenia and in postmortem schizophrenia brain. Synapse 61: 303–309.
• Sesack SR, Carr DB. 2002. Selective prefrontal cortex inputs to dopamine cells: Implications for schizophrenia. Physiol Behav 77: 513–517.
• Shapiro M. 2001. Plasticity, hippocampal place cells, and cognitive maps. Arch Neurol 58: 874–881.
• Sher E, Chen Y, Sharples TJ, Broad LM, Benedetti G, et al. 2004. Physiological roles of neuronal nicotinic receptor subtypes: New insights on the nicotinic modulation of neurotransmitter release, synaptic transmission and plasticity. Curr Top Med Chem 4: 283–297.
• Shibuya H, Mori H, Toru M. 1992. Sigma receptors in schizophrenic cerebral cortices. Neurochem Res 17: 983–990.
• Shire D, Carillon C, Kaghad M, Calandra B, Rinaldi-Carmona M, et al. 1995. An amino-terminal variant of the central cannabinoid receptor resulting from alternative splicing. J Biol Chem 270: 3726–3731.
• Sidhu A, Niznik HB. 2000. Coupling of dopamine receptor subtypes to multiple and diverse G proteins. Int J Dev Neurosci 18: 669–677.
• Simeone TA, Sanchez RM, Rho JM. 2004. Molecular biology and ontogeny of glutamate receptors in the mammalian central nervous system. J Child Neurol 19: 343–360;
• Simpson MD, Slater P, Royston MC, Deakin JF. 1991. Alterations in phencyclidine and sigma binding sites in schizophrenic brains. Effects of disease process and neuroleptic medication. Schizophr Res 6: 41–48.
• Simpson MD, Lubman DI, Slater P, Deakin JF. 1996. Autoradiography with [3H]8-OH-DPAT reveals increases in 5-HT(1A) receptors in ventral prefrontal cortex in schizophrenia. Biol Psychiatry 9(11): 919–928.
• Skeberdis VA, Lan J, Opitz T, Zheng X, Bennett MV, et al. 2001. mGluR1-mediated potentiation of NMDA receptors involves a rise in intracellular calcium and activation of protein kinase C. Neuropharmacology 40: 856–865.
• Smith GB, Olsen RW. 1995. Functional domains of GABAA receptors. Trends Pharmacol Sci 16: 162–168.
• Sodhi MS, Burnet PW, Makoff AJ, Kerwin RW, Harrison PJ. 2001. RNA editing of the 5-HT(2C) receptor is reduced in schizophrenia. Mol Psychiatry 6(4): 373–379.
• Sokolov BP. 1998. Expression of NMDAR1, GluR1, GluR7, and KA1 glutamate receptor mRNAs is decreased in frontal cortex of “neuroleptic-free” schizophrenics: Evidence on reversible up-regulation by typical neuroleptics. J Neurochem 71: 2454–2464.
• Soriani O, Foll FL, Roman F, Monnet FP, Vaudry H, et al. 1999. A-Current down-modulated by sigma receptor in frog pituitary melanotrope cells through a G protein-dependent pathway. J Pharmacol Exp Ther 289: 321–328.
• Sossa KG, Court BL, Carroll RC. 2006. NMDA receptors mediate calcium-dependent, bidirectional changes in dendritic PICK1 clustering. Mol Cell Neurosci 31: 574–585.
• Spooren W, Riemer C, Meltzer H. 2005. Opinion: NK3 receptor antagonists: The next generation of antipsychotics? Nat Rev Drug Discov 4: 967–975.
• Squires RF, Lajtha A, Saederup E, Palkovits M. 1993. Reduced [3H]flunitrazepam binding in cingulate cortex and hippocampus of postmortem schizophrenic brains: Is selective loss of glutamatergic neurons associated with major psychoses? Neurochem Res 18: 219–223.
• Squires RF, Saederup E. 2000. Additivities of compounds that increase the numbers of high affinity [3H]muscimol binding sites by different amounts define more than 9 GABA(A) receptor complexes in rat forebrain: Implications for schizophrenia and clozapine research. Neurochem Res 25: 1587–1601.
• Srivastava S, Ziff EB. 1999. ABP: A novel AMPA receptor binding protein. Ann N Y Acad Sci 868: 561–564.
• Standley S, Roche KW, McCallum J, Sans N, Wenthold RJ. 2000. PDZ domain suppression of an ER retention signal in NMDA receptor NR1 splice variants. Neuron 28: 887–898.
• Stefanis NC, Bresnick JN, Kerwin RW, Schofield WN, McAllister G. 1998. Elevation of D4 dopamine receptor mRNA in postmortem schizophrenic brain. Brain Res Mol Brain Res 53: 112–119.
• Stephenson FA. 2001. Subunit characterization of NMDA receptors. Curr Drug Targets 2: 233–239.
• Stine CD, Lu W, Wolf ME. 2001. Expression of AMPA receptor flip and flop mRNAs in the nucleus accumbens and prefrontal cortex after neonatal ventral hippocampal lesions. Neuropsychopharmacology 24: 253–266.
• Stowell JN, Craig AM. 1999. Axon/dendrite targeting of metabotropic glutamate receptors by their cytoplasmic carboxy-terminal domains. Neuron 22: 525–536.
• Sullivan JM. 1999. Mechanisms of cannabinoid-receptor-mediated inhibition of synaptic transmission in cultured hippocampal pyramidal neurons. J Neurophysiol 82: 1286–1294.
• Sumiyoshi T, Stockmeier CA, Overholser JC, Thompson PA, Meltzer HY. 1995. Dopamine D4 receptors and effects of guanine nucleotides on [3H]raclopride binding in postmortem caudate nucleus of subjects with schizophrenia or major depression. Brain Res 681: 109–116.
• Surprenant A, Shen KZ, North RA, Tatsumi H. 1990. Inhibition of calcium currents by noradrenaline, somatostatin and opioids in guinea-pig submucosal neurones. J Physiol 431: 585–608.
• Suzuki T, Ito J, Takagi H, Saitoh F, Nawa H, et al. 2001. Biochemical evidence for localization of AMPA-type glutamate receptor subunits in the dendritic raft. Brain Res Mol Brain Res 89: 20–28.
• Takumi Y, Matsubara A, Rinvik E, Ottersen OP. 1999. The arrangement of glutamate receptors in excitatory synapses. Ann NY Acad Sci 868: 474–482.
• Tamminga CA. 1998. Schizophrenia and glutamatergic transmission. Crit Rev Neurobiol 12: 21–36.
• Tamminga CA, Holcomb HH. 2005. Phenotype of schizophrenia: A review and formulation. Mol Psychiatry 10: 27–39.
• Tamminga CA, Lahti AC, Medoff DR, Gao XM, Holcomb HH. 2003. Evaluating glutamatergic transmission in schizophrenia. Ann NY Acad Sci 1003: 113–118.
• Tanoue A, Koshimizu TA, Tsujimoto G. 2002. Transgenic studies of alpha(1)-adrenergic receptor subtype function. Life Sci 71: 2207–2215.
• Tepper JM, Bolam JP. 2004. Functional diversity and specificity of neostriatal interneurons. Curr Opin Neurobiol 14: 685–692.
• Tice MA, Hashemi T, Taylor LA, McQuade RD. 1996. Distribution of muscarinic receptor subtypes in rat brain from postnatal to old age. Brain Res Dev Brain Res 92: 70–76.
• Tingley WG, Roche KW, Thompson AK, Huganir RL. 1993. Regulation of NMDA receptor phosphorylation by alternative splicing of the C-terminal domain. Nature 364: 70–73.
• Tokuyama S, Hirata K, Yoshida A, Maruo J, Matsuno K, et al. 1999. Selective coupling of mouse brain metabotropic sigma receptor with recombinant Gi1. Neurosci Lett 268: 85–88.
• Tomita S, Stein V, Stocker TJ, Nicoll RA, Bredt DS. 2005. Bidirectional synaptic plasticity regulated by phosphorylation of stargazin-like TARPs. Neuron 45: 269–277.
• Tooney PA, Crawter VC, Chahl LA. 2001. Increased tachykinin NK(1) receptor immunoreactivity in the prefrontal cortex in schizophrenia. Biol Psychiatry 49: 523–527.
• Toro C, Deakin JF. 2005. NMDA receptor subunit NRI and postsynaptic protein PSD-95 in hippocampus and orbitofrontal cortex in schizophrenia and mood disorder. Schizophr Res 80: 323–330.
• Toru M. 1998. Biological research on schizophrenia. Psychiatry Clin Neurosci 52(Suppl.): S170–S172.
• Toyooka K, Iritani S, Makifuchi T, Shirakawa O, Kitamura N, et al. 2002. Selective reduction of a PDZ protein, SAP-97, in the prefrontal cortex of patients with chronic schizophrenia. J Neurochem 83: 797–806.
• Trist DG. 2000. Excitatory amino acid agonists and antagonists: Pharmacology and therapeutic applications. Pharm Acta Helv 74: 221–229.
• Tsou K, Brown S, Sanudo-Pena MC, Mackie K, Walker JM. 1998. Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience 83: 393–411.
• Tu JC, Xiao B, Naisbitt S, Yuan JP, Petralia RS, et al. 1999. Coupling of mGluR/Homer and PSD-95 complexes by the Shank family of postsynaptic density proteins. Neuron 23: 583–592.
• Van den Pol AN. 1994. Metabotropic glutamate receptor mGluR1 distribution and ultrastructural localization in hypothalamus. J Comp Neurol 349: 615–632.
• van der Zee EA, Luiten PG. 1999. Muscarinic acetylcholinereceptors in the hippocampus, neocortex and amygdala: A review of immunocytochemical localization in relation to learning and memory. Prog Neurobiol 58: 409–471.
• Van Kammen DP. 1977. Gamma-Aminobutyric acid (Gaba) and the dopamine hypothesis of schizophrenia. Am J Psychiatry 134: 138–143.
• Vanhoose AM, Winder DG. 2003. NMDA and beta1-adrenergic receptors differentially signal phosphorylation of glutamate receptor type 1 in area CA1 of hippocampus. J Neurosci 23: 5827–5834.
• Varga EV, Yamamura HI, Rubenzik MK, Stropova D, Navratilova E, et al. 2003. Molecular mechanisms of excitatory signaling upon chronic opioid agonist treatment. Life Sci 74: 299–311.
• Vawter MP, Crook JM, Hyde TM, Kleinman JE, Weinberger DR, et al. 2002. Microarray analysis of gene expression in the prefrontal cortex in schizophrenia: A preliminary study. Schizophr Res 58: 11–20.
• Vigot R, Barbieri S, Brauner-Osborne H, Turecek R, Shigemoto R, et al. 2006. Differential compartmentalization and distinct functions of GABAB receptor variants. Neuron 50: 589–601.
• Vogt BA, Finch DM, Olson CR. 1992. Functional heterogeneity in cingulate cortex: The anterior executive and posterior evaluative regions. Cereb Cortex 2: 435–443.
• Vohora D. 2004. Histamine-selective H3 receptor ligands and cognitive functions: An overview. IDrugs 7: 667–673.
• Volk DW, Lewis DA. 2002. Impaired prefrontal inhibition in schizophrenia: Relevance for cognitive dysfunction. Physiol Behav 77: 501–505.
• Volk DW, Pierri JN, Fritschy JM, Auh S, Sampson AR, et al. 2002. Reciprocal alterations in pre- and postsynaptic inhibitory markers at chandelier cell inputs to pyramidal neurons in schizophrenia. Cereb Cortex 12: 1063–1070.
• Volpicelli LA, Levey AI. 2004. Muscarinic acetylcholine receptor subtypes in cerebral cortex and hippocampus. Prog Brain Res 145: 59–66.
• Wafford KA, Bain CJ, Le Bourdelles B, Whiting PJ, Kemp JA. 1993. Preferential co-assembly of recombinant NMDA receptors composed of three different subunits. Neuroreport 4: 1347–1349.
• Wang JB, Imai Y, Eppler CM, Gregor P, Spivak CE, et al. 1993. mu opiate receptor: CDNA cloning and expression. Proc Natl Acad Sci USA 90: 10230–10234.
• Wedzony K, Chocyk A, Mackowiak M, Fijal K, Czyrak A. 2000. Cortical localization of dopamine D4 receptors in the rat brain--immunocytochemical study. J Physiol Pharmacol 51: 205–221.
• Weidenhofer J, Yip J, Zavitsanou K, Huang XF, Chahl LA, et al. 2006. Immunohistochemical localisation of the NK1 receptor in the human amygdala: Preliminary investigation in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 30: 1313–1321.
• Weissman AD, Casanova MF, Kleinman JE, London ED, De Souza EB. 1991. Selective loss of cerebral cortical sigma, but not PCP binding sites in schizophrenia. Biol Psychiatry 29: 41–54.
• Westlake TM, Howlett AC, Bonner TI, Matsuda LA, Herkenham M. 1994. Cannabinoid receptor binding and messenger RNA expression in human brain: An in vitro receptor autoradiography and in situ hybridization histochemistry study of normal aged and Alzheimer’s brains. Neuroscience 63: 637–652.
• Whitaker PM, Crow TJ, Ferrier IN. 1981. Tritiated LSD binding in frontal cortex in schizophrenia. Arch Gen Psychiatry 38(3): 278–280.
• Whiting PJ, Bonnert TP, McKernan RM, Farrar S, Le Bourdelles B, et al. 1999. Molecular and functional diversity of the expanding GABA-A receptor gene family. Ann NY Acad Sci 868: 645–653.
• Wijkhuisen A, Sagot MA, Frobert Y, Creminon C, Grassi J, et al. 1999. Identification in the NK1 tachykinin receptor of a domain involved in recognition of neurokinin A and septide but not of substance P. FEBS Lett 447: 155–159.
• Wilke RA, Lupardus PJ, Grandy DK, Rubinstein M, Low MJ, et al. 1999. K+ channel modulation in rodent neurohypophysial nerve terminals by sigma receptors and not by dopamine receptors. J Physiol 517(Pt 2): 391–406.
• Williams JT, Christie MJ, Manzoni O. 2001. Cellular and synaptic adaptations mediating opioid dependence. Physiol Rev 81: 299–343.
• Woo TU, Walsh JP, Benes FM. 2004. Density of glutamic acid decarboxylase 67 messenger RNA-containing neurons that express the N-methyl-D-aspartate receptor subunit NR2A in the anterior cingulate cortex in schizophrenia and bipolar disorder. Arch Gen Psychiatry 61: 649–657.
• Wuster M, Schulz R, Herz A. 1979. Specificity of opioids towards the mu-, delta- and epsilon-opiate receptors. Neurosci Lett 15: 193–198.
• Xing G, Zhang L, Russell S, Post R. 2006. Reduction of dopamine-related transcription factors Nurr1 and NGFI-B in the prefrontal cortex in schizophrenia and bipolar disorders. Schizophr Res 84: 36–56.
• Yamada T, Endoh T, Suzuki T. 1999. Inhibition of calcium channels by neurocinin receptor and signal transduction in hamster submandibular ganglion cells. J Auton Nerv Syst 76: 1–8.
• Yanai K, Tashiro M. 2007. The physiological and pathophysiological roles of neuronal histamine: An insight from human positron emission tomography studies. Pharmacol Ther 113: 1–15.
• Yang CR, Seamans JK, Gorelova N. 1999. Developing a neuronal model for the pathophysiology of schizophrenia based on the nature of electrophysiological actions of dopamine in the prefrontal cortex. Neuropsychopharmacology 21: 161–194.
• Yasuda K, Raynor K, Kong H, Breder CD, Takeda J, et al. 1993. Cloning and functional comparison of kappa and delta opioid receptors from mouse brain. Proc Natl Acad Sci USA 90: 6736–6740.
• Yuan LL, Adams JP, Swank M, Sweatt JD, Johnston D. 2002. Protein kinase modulation of dendritic K+ channels in hippocampus involves a mitogen-activated protein kinase pathway. J Neurosci 22: 4860–4868.
• Zagon IS, Gibo DM, McLaughlin PJ. 1991. Zeta (zeta), a growth-related opioid receptor in developing rat cerebellum: Identification and characterization. Brain Res 551: 28–35.
• Zamanillo D, Andreu F, Ovalle S, Perez MP, Romero G, et al. 2000. Up-regulation of sigma(1) receptor mRNA in rat brain by a putative atypical antipsychotic and sigma receptor ligand. Neurosci Lett 282: 169–172.
• Zavitsanou K, Garrick T, Huang XF. 2004a. Selective antagonist [3H]SR141716A binding to cannabinoid CB1 receptors is increased in the anterior cingulate cortex in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 28: 355–360.
• Zavitsanou K, Katsifis A, Mattner F, Huang XF. 2004b. Investigation of m1/m4 muscarinic receptors in the anterior cingulate cortex in schizophrenia, bipolar disorder, and major depression disorder. Neuropsychopharmacology 29: 619–625.
• Zavitsanou K, Katsifis A, Yu Y, Huang XF. 2005. M2/M4 muscarinic receptor binding in the anterior cingulate cortex in schizophrenia and mood disorders. Brain Res Bull 65: 397–403.
• Zavitsanou K, Ward PB, Huang XF. 2002. Selective alterations in ionotropic glutamate receptors in the anterior cingulate cortex in schizophrenia. Neuropsychopharmacology 27: 826–833.
• Zhao C, Slevin JT, Whiteheart SW. 2007. Cellular functions of NSF: Not just SNAPs and SNAREs. FEBS Lett: 581: 2140–2149.
• Zhao C, Xu Z, Chen J, Yu Z, Tong KL, et al. 2006. Two isoforms of GABA(A) receptor beta2 subunit with different electrophysiological properties: Differential expression and genotypical correlations in schizophrenia. Mol Psychiatry 11: 1092–1105.
• Zhou F, Yao HH, Wu JY, Yang YJ, Ding JH, et al. 2006. Activation of Group II/III metabotropic glutamate receptors attenuates LPS-induced astroglial neurotoxicity via promoting glutamate uptake. J Neurosci Res 84: 268–277.
• Zhou FM, WilsonC, Dani JA. 2003. Muscarinic and nicotinic cholinergic mechanisms in the mesostriatal dopamine systems. Neuroscientist 9: 23–36.
• Zhou FM, Wilson CJ, Dani JA. 2002. Cholinergic interneuron characteristics and nicotinic properties in the striatum. J Neurobiol 53: 590–605.
• Zukin SR, Brady KT, Slifer BL, Balster RL. 1984. Behavioral and biochemical stereoselectivity of sigma opiate/PCP receptors. Brain Res 294: 174–177.